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ABSTRACT
Protein Kinase B/AKT, a serine/threonine kinase with three isoforms (AKT1-3), is
downstream of phosphatidylinositol 3-kinase (PI3K), and signals through the phosphorylation and
subsequent activation or inhibition of downstream substrates, such as mammalian target of
rapamycin complex 1 (mTORC1) or glycogen synthase kinase 3 beta (GSK-3β), respectively. The
AKT1 isoform is predominantly recognized for regulation of cell survival, growth, and
proliferation, due to its constitutive activation in pancreatic cancers (e.g., islet cell carcinoma and
pancreatic adenocarcinoma). The progression of pancreatic ductal adenocarcinoma (PDAC), the
most lethal common cancer, is initiated by activation mutations of the KRas oncogene. This leads
to additional molecular changes, such as activation of the AKT1 oncogene, which drives PDAC
progression and tumor formation. By mating transgenic mice with activation of KRas (PdxCre;LSL-KRasG12D) and mice with activation of AKT1 (Pdx- Tta;TetO-MyrAKT1) we were
able to produce mice with two activated oncogenes (AKT1Myr/KRasG12D) for comparative
studies. Kaplan-Meier survival curves, histology, and genomic/proteomic analysis were used to
characterize the incidence and frequency of histological (e.g. presence of mucin-4 in pancreatic
intraepithelial neoplasms) and genetic (e.g. loss of tumor suppressors p16Ink4a and p19Arf)
alterations known to commonly occur in human pancreatic cancer, as well as delineate the role of
AKT1 in accelerating pancreatic tumor progression and metastasis.

We determined that

AKT1Myr/KRasG12D mice, unlike other PDAC mouse models, accurately mimic the human
PDAC progression molecularly, structurally, and temporally.
Interestingly, the AKT1Myr and AKT1Myr/KRasG12D models both exhibit a pre-tumor,
diabetic phenotype. While, AKT1 hyperactivation in various cancers has been thoroughly studied,
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its role in glucose metabolism has been noted, but comparatively overlooked. As early as the
1900s a relationship between diabetes and pancreatic cancer has been proposed. With 80% of
PDAC patients suffering from hyperglycemia or diabetes prior to diagnosis, one prevailing theory
is that new onset diabetes is an early marker for pancreatic cancer. This is also supported by
experimental and clinical studies, such as the resolution of diabetes with tumor removal and the
induction of hyperglycemia with the implantation of cancer cell lines. To better understand the
role of AKT1 and its hyperactivation in glucose metabolism, AKT1Myr mice were characterized
via metabolic (e.g. glucose/insulin tolerance test) and histological (e.g. immunohistochemistry)
studies. Beginning at weaning, 3 weeks of age, the glucose intolerant AKT1Myr mice exhibited
non-fasted hyperglycemia, which progressed to fasted hyperglycemia by 5 months of age. The
glucose intolerance was attributed to a fasted hyperglucagonemia, and hepatic insulin resistance
detectable by reduced phosphorylation of the insulin receptor following insulin injection into the
inferior vena cava. Additionally, AKT1Myr/KRasG12D mice currently being studied, appear to
display a more severe diabetic phenotype, with fasted hyperglycemia noticeable at an earlier age,
fasted hyperglucagonemia, polyuria, muscle wasting, and bloating. Treatment of both models with
doxycycline diet, to turn-off the transgene, caused attenuation of the non-fasted and fasted
hyperglycemia, thus affirming AKT1 hyperactivation as the trigger. These newly revealed roles
of AKT1, along with future studies of these mouse models, will better delineate the molecular
mechanisms responsible for the individual and joint roles of AKT1 and KRas in pancreatic cancer
oncogenesis, the initiation of cancer associated diabetes, and the association of these two diseases.
.
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CHAPTER 1: GENERAL INTRODUCTION
Protein Kinase B/AKT
Protein Kinase B (AKT), a serine threonine kinase in the phosphatidylinositol 3-kinase
(PI3K) signaling pathway (Figure 1), plays a vital role in cell signaling, making its abnormal loss
or gain of function the epicenter of a variety of diseases, including cancer and diabetes mellitus
(Manning & Cantley 2007). The activation of AKT (Figure 2), which is downstream of hormones,
mitogens, cytokines and growth factors, is tightly controlled by positive and negative regulators
within the pathway.

Binding of a ligand, such as insulin, to its receptor leads to the

phosphorylation of tyrosine residues on the intracellular domain of the receptor. PI3K binds to
these phosphotyrosine residues leading to conformational changes in the catalytic domain of PI3K
and subsequent activation. Activated PI3K phosphorylates membrane bound phosphatidylinositol
(3,4)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which
binds the PH domain of AKT recruiting it to the plasma membrane, where it is phosphorylated at
the Threonine 308 (T308) residue and partially activated by Phosphoinositide-Dependent Kinase1 (PDK1) (Alessi et al. 1997). Partial activation is sufficient to activate some downstream
substrates, such as mTORC1 (Vander Haar et al. 2007), but full activation requires additional
phosphorylation by mTORC2 (Sarbassov et al. 2005) or DNA-PK (Feng et al. 2004) at the Serine
473 residue (S473). AKT is negatively regulated by direct dephosphorylation of T308 and S473
by Protein Phosphatase 2A (PP2A) (Andjelković et al. 1996) and PH domain and leucine rich
repeat protein phosphatases (PHLPP1/2) (Brognard et al. 2007), respectively. It is also negatively
regulated by the indirect conversion of PIP3 to PIP2 by Phosphatase and Tensin Homolog (PTEN)
(Stambolic et al. 1998). Once fully activated, AKT signals through the phosphorylation and
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subsequent activation or inhibition of downstream substrates, allowing regulation of key cellular
processes such as survival, growth, proliferation, metabolism, protein synthesis, transcription,
apoptosis, and angiogenesis (Hemmings & Restuccia 2012).

AKT isoforms and function
It is believed that AKT controls such an array of diverse functions through its three
isoforms: AKT1 (PKBα), AKT2 (PKBβ), and AKT3 (PKBγ). The isoforms are structurally
analogous (Figure 3) consisting of: (1) a common NH2-terminal pleckstrin homology (PH) domain
which allows binding and translocation to the membrane; (2) a catalytic domain which contains
the threonine residue for partial activation; and (3) a carboxyl terminal extension containing the
serine for full activation. AKT isoforms are encoded by three different genes on different
chromosomes. They also have differential tissue expression and varying functions (Figure 4) (Hay
2011; Song et al. 2005). AKT1 is ubiquitously expressed in mammalian tissues and predominately
recognized for its role in cell growth, proliferation, and survival (Cho et al. 2001). AKT2 is highly
expressed in insulin responsive tissues (e.g., liver, skeletal muscle, and adipose tissues) and is
therefore recognized for its role in glucose metabolism and insulin signaling (Cho et al. 2001;
Garofalo et al. 2003). AKT3 is highly expressed in brain and is vital for brain development
(Tschopp et al. 2005). Differences in the subcellular locations of the isoforms have also been
identified with AKT1 in the cytoplasm, AKT2 at the mitochondria, and AKT3 in the nucleus (Santi
& Lee 2010). Functional differences have largely been identified via single isoform knockout
mouse studies. However, double AKT isoform knockout studies reveal possible compensation
among the isoforms, making further examination necessary to fully understand isoform functional
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specificity and to develop therapeutic treatments targeting AKT isoform-specific functions
(Gonzalez & McGraw 2009).

AKT and Cancer
AKT is a well-known survival protein, blocking apoptosis in several ways, which includes
but is not limited to: (1) phosphorylation of BAD (Serine 136) to inhibit its apoptotic activity
(Datta et al. 1999); (2) phosphorylation and inhibition of Caspase-9 (Serine 196) (Cardone et al.
1998), and (3) transcriptional regulation of pro- and anti-apoptotic genes (Song et al. 2005). In
addition to its anti-apoptotic activity elevated AKT leads to increased cell migration, reduced
cellular adhesion, and promotion of epithelial to mesenchymal transition (EMT) (Enomoto et al.
2005; Grille et al. 2003; Tanno et al. 2001). Therefore, it is not surprising that the hyperactivation
of AKT has been conclusively linked to the development of various human cancers (Figure 5),
such as gastric, ovarian, prostate, breast, pancreatic, melanoma, and colorectal cancers (Staal 1987;
Carpten et al. 2007; Cheng et al. 1996; Stahl et al. 2004; Schlieman et al. 2003; Toker 2012). AKT
hyperactivation can occur due to increased growth factor stimulation, presence of oncogenic
upstream regulators (e.g., PI3K), or loss of negative regulators (e.g., PTEN). Additionally, other
pathways, such as the RAS/RAF/MEK/ERK pathway, can also be activated in cancers, such as
pancreatic ductal adenocarcinoma (PDAC), further activating shared targets such as AKT
(Gonzalez & McGraw 2009).

AKT and Pancreatic Ductal Adenocarcinoma
PDAC, the most lethal common cancer largely due to late diagnosis, develops primarily
from precursor lesions, called pancreatic intraepithelial neoplasias (PanINs). PanINs are classified
3

based upon the increasing degree of structural abnormality in the tissue (Figure 6). PanIN1 lesions
are subdivided into flat (PanIN1A) and papillary types (PanIN1B). PanIN2s have loss of polarity,
nuclear crowding, cell enlargement, and increased nuclear staining. PanIN3s have severe nuclear
abnormality, luminal necrosis, and epithelial cell budding into the ducts (Murphy et al. 2013). On
average it takes 17 years for the PanINs to progress to the aggressive PDAC which has a survival
rate of only four to six months after diagnosis (Hidalgo et al. 2015).
Activation mutations of Ras, specifically the Kristin Ras isoform (KRas), are found in
PanIN1A lesions and 90% of PDACs, making it an important tumor initiating event (Löhr et al.
2005; Morris et al. 2010). KRas activation subsequently leads to additional molecular changes,
such as activation of the AKT oncogene and loss of tumor suppressors, which further drives PDAC
progression and tumor formation (Ryan et al. 2014). Further studies into the genetic changes that
occur in early PanINs may provide an opportunity for early diagnosis and ultimately an increased
survival rate. The unavailability of early-stage tissue from patients has hampered the search for
such genetic biomarkers, and made the use of pancreatic cancer mouse models of upmost
importance. In chapter 2 we used a PDAC mouse model, with activation of KRas and AKT1
(AKT1Myr/KRasG12D), to characterize the incidence and frequency of histological (e.g. presence
of mucin-4 in pancreatic intraepithelial neoplasms) and genetic (e.g. loss of tumor suppressors
p16Ink4a and p19Arf) alterations known to commonly occur in human pancreatic cancer, as well
as delineate the role of AKT1 in accelerating pancreatic tumor progression and metastasis. We
determined that AKT1Myr/KRasG12D mice, unlike other PDAC mouse models, accurately mimic
the human PDAC progression molecularly, structurally, and most importantly temporally. Other
PDAC models (mice with KRasG12D activation and Pten homozygous deletion) have rapid (<3
4

weeks) tumor development, while our model has a slower progression (~54 weeks) allowing for
therapeutic studies that can block tumor progression at the PanIN or early carcinoma stage, before
there is excessive tissue damage.

Glucose Metabolism
Insulin and glucagon are classified as the chief regulators of glucose homeostasis (Figure
7). Glucose homeostasis, maintaining blood glucose concentrations within a narrow range, is vital
as glucose is the main fuel source for the brain, which can neither synthesize nor store glucose
long term. Hypoglycemia, low blood glucose levels, can impair brain function and eventually lead
to convulsions and death (Shrayyef & Gerich 2010). Whereas hyperglycemia, high blood glucose
levels, can lead to cardiovascular damage, retinopathy, nephropathy, and neuropathy (Nathan
1993). Therefore it is essential to maintain stable blood glucose concentrations at all times,
avoiding tissue damage and disease.
Homeostasis is maintained by balancing the rate of glucose entering the circulation and the
rate of glucose leaving the circulation. During fasting, when blood glucose levels are low,
glucagon is secreted by pancreatic α-cells to induce glycogenolysis and gluconeogenesis in the
liver.

Glycogenolysis is the breakdown of glycogen, the stored form of glucose, and

gluconeogenesis is the formation of glucose from lactate and amino acids. Both processes result
in the release of glucose from the liver into circulation. After a meal blood glucose levels spike
and insulin is released by pancreatic β-cells to initiate glucose uptake by skeletal muscle and
adipose tissue. Insulin also inhibits endogenous glucose production by suppressing glucagon
secretion in the pancreas and promoting glycogenesis, conversion of glucose to glycogen, in the
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liver. While this “bi-hormonal” explanation for glucose metabolism and regulation is widely
accepted, it is relatively flawed, as the system is actually quite complex with many contributing
parts, such as AKT (Aronoff et al. 2004).

AKT and Glucose Metabolism
AKT is predominantly recognized for its role in the regulation of cell survival, growth, and
proliferation, but it also plays a role in glucose metabolism, which has been noted, but
comparatively overlooked. Studies conducted in C elegans, Drosophilia, and mice have proven
AKT, which is downstream of insulin and insulin-like growth factor 1 (IGF1), is involved in the
coupling of extracellular signals and metabolism (Teleman 2009; Panowski & Dillin 2009; Peng
et al. 2003). Activation of the insulin receptor leads to the phosphorylation and activation of AKT,
which subsequently phosphorylates downstream effectors, such as FoxO and mTORC1, inhibiting
hepatic glucose production (Nakae et al. 2002) and inducing insulin biosynthesis (Leibiger et al.
1998), respectively. AKT has also been shown to facilitate the insulin induced translocation of
GLUT 4 to the plasma membrane of fat and muscle cells allowing glucose uptake and the lowering
of postprandial blood glucose levels (Huang & Czech 2007; Katome et al. 2003).
As AKT2 is highly expressed in insulin responsive tissues it has been identified as a
primary regulator of glucose metabolism.

This is supported by the insulin resistance,

hyperinsulinemia, and glucose intolerance observed in AKT2 knockout mice (AKT2-/-) (Cho et
al. 2001; Garofalo et al. 2003). Initially AKT1 and 3 were deemed unnecessary for glucose
homeostasis, as AKT1 (AKT1-/-) and AKT3 (AKT3-/-) knockout mice have normal glucose
tolerance and insulin signaling, but impaired fetal/adult growth and reduced brain size,
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respectively (Cho et al. 2001; Tschopp et al. 2005). However, a role for AKT1 in glucose
homeostasis became evident with the metabolic analysis of compound isoform knockout mice
(Figure 4). One such study revealed that haplodeficiency of AKT1 in AKT2-/- mice resulted in a
more severe diabetic phenotype, characterized by fed and fasted hyperglycemia, glucose
intolerance, insulin resistance, and hyperinsulinemia (Chen et al. 2009).
Although AKT1 hyperactivation has been frequently observed in pancreatic cancers
(Schlieman et al. 2003; Missiaglia et al. 2010), there are limited studies regarding AKT1
hyperactivation and glucose homeostasis (Bernal-Mizrachi et al. 2001; Tuttle et al. 2001; Kushner
et al. 2005; Stiles et al. 2006).

In chapter three we metabolically characterize mice with

myristoylated, membrane-bound and therefore activated AKT1 (AKT1Myr). We report that this
strain of mice exhibit non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by
20 weeks of age, largely due to fasted hyperglucagonemia. We confirm that this pre-diabetic
phenotype is due to AKT1 hyperactivation, as doxycycline treatment to turn off the transgene
attenuates the elevated blood glucose levels. Collectively, this pre-diabetic model highlights a
novel glucagon-mediated mechanism by which AKT1 hyperactivation, as seen in many cancers,
affects glucose homeostasis, possibly shedding light on the association between pancreatic cancer
and diabetes.

Pancreatic Cancer and Diabetes
As early as the 1900s a relationship between diabetes and pancreatic cancer has been
proposed. Based upon experimental and clinical evidence, there are two prevailing theories: (1)
long-term diabetes induces pancreatic cancer and (2) new onset diabetes is an early marker for
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pancreatic cancer. The first theory, that long-term diabetes induces pancreatic cancer, is based
upon evidence that high glucose levels can induce replication/proliferation (Butler et al. 2010;
Brand et al. 2011; Han et al. 2011), epithelial-mesenchymal transition (Lee & Han 2010; Javle et
al. 2007), and oxidative stress (Cullen et al. 2003). The second theory, that new onset diabetes is
an early marker for pancreatic cancer, is based upon the following evidence: tumor removal
resolves diabetes (Permert et al. 1993; Pannala et al. 2008) and implantation of cancer cell lines
can induce hyperglycemia (Wang et al. 1997; Basso et al. 1995; Valerio et al. 2004). This theory
is also strongly supported by the fact that 80% of PDAC patients suffer from hyperglycemia or
diabetes prior to diagnosis (Wang et al. 2003). Additionally, a meta-analysis of 35 cohort studies
revealed that diabetes was associated with a 94% increased risk of PDAC, which decreased with
the duration of diabetes suggesting that the diabetes is caused by the cancer (Ben et al. 2011). So,
while the association between diabetes and pancreatic cancer appears firm the specific mechanisms
involved remain debatable.
In chapter 4 we begin to characterize the diabetic phenotype observed in
AKT1Myr/KRasG12D transgenic mice to better understand how the presence of two oncogenes
(AKT1 and KRas) cooperate to affect glucose homeostasis. Similar to AKT1Myr mice, yet more
severe, AKT1Myr/KRasG12D mice exhibit hyperglucagonemia induced non-fasted hyperglycemia
as early as weaning and fasted hyperglycemia by 3 months of age. AKT1Myr/KRasG12D mice
also suffer from polyuria, muscle wasting, and bloating, which is not seen in AKT1Myr mice. Once
fully characterized this diabetic model will provide an avenue to better understand the molecular
mechanisms behind the association of pancreatic cancer and diabetes. With 256 million adults
worldwide suffering from type 2 diabetes, and projections likely to increase by 54.1% in the next
8

twenty years, it is vital that we understand this association, whether to prevent the formation of
pancreatic cancer or to treat pancreatic cancer while it is still in the early stages (Shaw et al. 2010).
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Figures and Tables

Figure 1: Signaling events activating PKB/AKT and cellular functions regulated by PKB/AKT.
Reprinted by permission: Hemmings BA & Restuccia DF 2012 PI3K-PKB/AKT pathway. Cold
Spring Harb Perspect Biol 2012;4:a011189, with copyright to Cold Spring Harbor Laboratory
Press.
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Figure 2: PKB/AKT activation downstream of RTKs via the PI3K pathway.
Reprinted by permission: Hemmings BA & Restuccia DF 2012 PI3K-PKB/AKT pathway. Cold
Spring Harb Perspect Biol 2012;4:a011189, with copyright to Cold Spring Harbor Laboratory
Press.
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Figure 3: AKT isoform analogous structures.
Reprinted by permission from Macmillan Publishers Ltd: [Oncogene] (Kumar CC & Madison V
2005 AKT crystal structure and AKT-specific inhibitors. Oncogene24 7493-7501.), copyright
(2005).
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Figure 4: AKT isoform functionality knockout mice studies.
Created by author based upon articles referenced in the introduction.
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Figure 5: AKT activation in human cancers.
Reprinted by permission from Macmillan Publishers Ltd: [Oncogene] (Altomare DA & Testa JR
2005 Perturbations of the AKT signaling pathway in human cancer. Oncogene24 7455-7464.),
copyright (2005).
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Figure 6: Diagram of the histology of precursor lesions and PDAC.
Republished with permission of [Dove Medical Press Ltd.], from [The impact of hypoxia in
pancreatic cancer invasion and metastasis, Angela Yuen, Begoña Díaz, Volume 2014:2,];
permission conveyed through Copyright Clearance Center, Inc. ”
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Figure 7: Glucose homeostasis – Roles of insulin and glucagon
Reprinted with permission: Aronoff SL, Berkowitz K, Shreiner B & Want L 2004 Glucose
Metabolism and Regulation: Beyond Insulin and Glucagon. Diabetes Spectrum3 183190.
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CHAPTER 2:
CONSTITUTIVELY ACTIVE AKT1 COOPERATES WITH KRAS(G12D)
TO ACCELERATE IN VIVO PANCREATIC TUMOR ONSET AND
PROGRESSION
Introduction
Activating KRAS mutations are present in virtually all human pancreatic adenocarcinomas
and occur with increasing frequency in later stage pancreatic intraepithelial neoplasia (PanIN)
lesions (Hruban et al. 2000; Hansel et al. 2003). To date, the model that most faithfully
recapitulates human PanIN development and its early progression is a mouse model that expresses
a Cre-activated KRas allele knocked into the endogenous KRas locus (Jackson et al. 2001) when
crossed with mice expressing a Pdx1-Cre recombinase transgene promoter (Gu et al. 2002).
Oncogenic KRasG12D in the progeny of the Cre matings developed PanINs within a few months,
with activation of the Notch pathway and overexpression of COX-2 and MMP-7 (Hingorani et al.
2003). This model thus offered the first recapitulation of human PanIN lesions, with low incidence
of progression to pancreatic adenocarcinoma (Hingorani et al. 2003).
In comparison, Pdx-Cre;Ptenlox/lox mice with pancreatic knockout of Pten display rapid
progression of pancreatic ductal metaplasia, development of PanINs, and low frequency of
malignant transformation (Stanger et al. 2005). Under normal conditions, mouse and human PTEN
functions as a dual-specificity protein phosphatase and a lipid phosphatase. Because PTEN
modulates phosphatidylinositol 3-kinase (PI3K)–AKT signaling, loss of PTEN tumor suppressor
function in pancreatic tumor progression further implicates the importance of AKT signaling in
pancreatic pathogenesis.
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Other mouse models of pancreatic cancer have been developed to study components of the
PI3K/PTEN/AKT signaling pathway. A previous study analyzed constitutively active mutant
AKT1 under control of Pdx-Cre, elastase-Cre, and rat insulin promoter-2–Cre expression (Elghazi
et al. 2009). Interestingly, premalignant lesions and acinar tumors were observed when expression
was driven by Pdx-Cre. Constitutively active myristoylated (Myr) AKT1 under rat insulin
promoter-2 was also shown to result in malignant transformation of islet cells to develop islet cell
carcinomas (Alliouachene et al. 2008). Most recently, a mouse model with a constitutively
activated catalytic subunit of PI3K was used to study the importance of PI3K signaling in KRasdriven pancreatic ductal adenocarcinoma (PDAC) initiation and maintenance (Eser et al. 2013)
and the requirement of 3-phosphoinositide dependent protein kinase 1 (PDK1) signaling for KRas
pancreatic cell plasticity and cancer. Of relevance to human pancreatic cancer, earlier reports
showed amplification and protein overexpression of AKT2 in human pancreatic cell lines (Cheng
et al. 1996), and both AKT1 and AKT2 were found in human PDACs and in metastases (Altomare
et al. 2003). AKT alterations are among the most commonly activated oncogenic changes in solid
tumors and activation of AKT isoforms is frequently attributed to down-regulation of PTEN tumor
suppressor or activation of upstream signaling components (activating PI3K mutations or
activating growth factor receptors). A prior study, using immunohistochemistry and tissue
microarrays, revealed that 34 of 133 (~ 25%) stage II PDACs exhibited loss of PTEN expression
(Foo et al. 2013). Haplo-insufficiency and occasional homozygous loss of PTEN have also been
found in human PDACs (Altomare et al. 2003). Overall, the data support a dosage-dependent role
for mouse and human PTEN and in the activation of downstream AKT (Hill et al. 2010).
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Herein, we report the first evidence describing the contribution of constitutively active
myristoylated AKT1 in vivo to pancreatic ductal tumor progression using genetically defined
transgenic models to delineate potential cooperation with Pdx-regulated expression of KRasG12D.
Collectively, these studies provide insights regarding the pathogenic implication of AKT
perturbations in combination with KRas oncogenic mutations to accelerate pancreatic progression
toward the development of invasive PDAC. In addition, we propose that this dual oncogene model
may offer long-term preclinical utility for testing of novel therapeutic strategies against pancreatic
tumor progression and an opportunity to intervene before extensive desmoplastic fibrosis and
irreversible tissue remodeling, which is a confounding problem in the treatment of late-stage
pancreatic disease.

Materials and Methods
Genetically Engineered Mice
Animal care and use was at Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC)-accredited facilities. Protocols were approved by
Institutional Animal Care and Use Committees at each respective institution and were compliant
with NIH guidelines. Pdx-tTA mice in an FVB/n background (Holland et al. 2002) were mated
with TetO-MyrAKT1 mice in a C57Bl/6 to generate Pdx-tTA;TetO-MyrAKT1 mice (Figure 12).
LSL-KRasG12D (Jackson et al. 2001) in a 129Sv/J background and Pdx-Cre (Gu et al. 2002) mice
in a C57Bl/6 were mated to generate Pdx-Cre;LSL-KRasG12D mice. The progeny were mated to
generate litters that were genotyped using DNA extracted from tail snips (Wizard Genomic DNA
Kit; Promega, Madison, WI) and were monitored for the tumor latency study. In total, 29 Pdx27

Cre;LSL-KRasG12D (designated KRasG12D mice) and 30 Pdx-tTA;TetO-MyrAKT1 (designated
AKT1Myr/KRasG12D mice) were followed. Animals were housed until times outlined and then
killed in accordance with American Veterinary Medical Association guidelines. Single Nucleotide
Polymorphism (SNP) analysis performed by Charles River Laboratories International
(Wilmington, MA) on randomly selected mice that were re-derived for the < 1 year analysis
revealed that the background of AKT1Myr/KRasG12D mutant mice was ~ 60% C57Bl/6N.

Genotype Analysis
Reactions were assembled using JumpStart REDTaq ReadyMix (Sigma, St Louis, MO).
Primers for polymerase chain reaction (PCR) detected presence of Pdx-Cre (5′ATCGCTGATTTGTGTAGTCGGT-3′; 5′-CAACAGTTGCGCAGCCTGAATG-3′), mutant or
non-recombined LSL-KRasG12D (5′-GTCGACAAGCTCATGCGGGTG-3′; 5′-AGCTAGCCACCATGGCTTGAGTACGTCTGCA-3′; 5′-CCTTTACAAGCGCACGCA-GACTGTAGA-3′),
heterozygous

knock-in

for

tTA

ACCATGAACAGTGAGGAGCAGTAC-3′;

into

the

endogenous

Pdx

gene

5′-GCGGGTTTCAGAGGAATTTGT-3′;

(5′5′-

TAGAAGGGGAAAGCTGGCAAG-3′; 5′-TCCAGATCGAAATCGTCTAGCG-3′), or presence
of

TetO-MyrAKT1

(5′-CTGGACTACTTGCACTCCGAGAAG-3′;

5′-

CTGTGTAGGGTCCTTCTTGAGCAG-3′).

Histologic Analysis
Specimens were fixed in 10% neutral buffered formalin (Surgipath Leica, Buffalo Grove,
IL) and paraffin embedded. Five-micrometer sections were cut with a rotary microtome (Leica).
Histologic staining used SelecTech hematoxylin and eosin (H&E) reagents (Surgipath). Staining
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with Alcian Blue or Trichrome (both from American MasterTech, Lodi, CA) was performed as
per manufacturers' instructions.
Antigen retrieval for immunohistochemistry was optimized with sodium citrate (pH 6.0)
or EDTA (pH 9.0; Leica). Primary antibodies were against phospho-AKT Ser473 (GeneTex,
Irvine, CA), phospho-mTor Ser2448 (Cell Signaling Technology, Danvers, MA), phosphop70S6K Thr389 (Upstate Cell Signaling, Temecula, CA or LifeSpan BioSciences, Seattle, WA),
and phospho-p70S6K Thr389 (Cell Signaling Technology), mucin-4 (Muc-4; LifeSpan
BioSciences), α-2 smooth muscle actin (α-SMA; Novus, Littleton, CO), cytokeratin 17/19 (Cell
Signaling Technology), and Ki67 (Abcam, Cambridge, MA). Detection used Polymer Refine
Detection reagents (Leica). A Bond-Max Immunostainer and Polymer Refine Detection reagents
(Leica) were used.

Cell Culture
Primary cells were collected following the killing of mice, and cells were derived from
phosphate-buffered saline–washed peritoneum and cultured using Dulbecco's modified Eagle's
medium (Cellgro Mediatech, Manassas, VA) supplemented with 15% FBS, 2 mM l-glutamine,
and 2 mM penicillin-streptomycin. Murine pancreatic cell cultures were maintained in Dulbecco's
modified Eagle's medium/10% FBS supplemented with 2 mM l-glutamine and penicillinstreptomycin. Human cell lines were from American Type Culture Collection (Manassas, VA) and
grown as recommended.
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Genomic PCR
Genomic DNA was extracted (Wizard Genomic DNA Isolation Kit; Promega), and PCRs
were performed with GoTaq Green Master Mix (Promega). Primers for PCR detected presence of
Tp53 (5′-CTTGACACCTGATCGTTACTC-3′ and 5′-CAGTCCTAACCCCACAGGCGG-3′),
p16Ink4a

(5′-TGGTCACACGACTGGGCGATTG-3′

and

5′-

GAATCGGGGTACGACCGAAAG-3′), p19Arf (5′-AGCATGGGTCGCAGGTTCTTGG-3′ and
5′-TTGAGGAGGACCGTGAAGCCGA-3′),
dehydrogenase

or

Gapdh

and

control

glyceraldehyde

(5′-AGGCCGGTGCTGAGTATGTC-3′

3-phosphate
and

5′-

TGCCTGCTTCACCACCTTCT-3′).

Western Blots
Whole-cell extracts were harvested from low passage cell cultures with 1 × cell lysis buffer
(Cell Signaling Technology) for protein, 1 mM phenylmethylsulfonyl fluoride (Sigma), and 2 mM
Halt protease and phosphatase inhibitor cocktail (Thermo, Waltham, MA). Protein was quantified
using the Bradford method. For Western blot analysis, 60 μg of each protein extract was combined
with Laemmli's sodium dodecyl sulfate sample buffer (final 1 ×) and denatured in a boiling water
bath for 5 minutes. Precision Plus (Bio-Rad Laboratories, Hercules, CA) protein standard and total
protein were separated on 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels
using a Mini-Protean Tetra Cell (Bio-Rad) unit set for 15 minutes at 20 mA and then 1 hour at 40
mA constant current. Proteins were transferred to Hybond ECL Nitrocellulose (GE Healthcare
Amersham, Pittsburgh, PA) at 25 V at 4°C for 2 hours using an XCell II Blot Module (Invitrogen
Life Technologies, Grand Island, NY). Antibodies for Western blots were against total AKT,
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phospho-AKT Ser473, and p53 (all from Cell Signaling Technology), mouse p16Ink4a (Santa
Cruz Biotechnology, Santa Cruz, CA), mouse p19Arf (Abcam), and actin (Millipore, Billerica,
MA). Secondary antibodies were anti-mouse (DyLight, Thermo) and anti-rabbit (IR Dye; LI-COR
Biosciences, Lincoln, NE), and signals were visualized using an Odyssey Infrared Imaging System
(LI-COR).

Results
Accelerated Frequency of PDACs in Double Mutant Mice Compared to Single Mutant Mice
The pancreatic tumor model uses the Pdx1 pancreas promoter to drive expression of
myristoylated, membrane-targeted, and therefore activated AKT. Specifically, it uses a dual
transgenic system with tetracycline operator (TetO) sequences fused to MyrAKT1 (Kovacic et al.
2003; Shiojima et al. 2005; Mukai et al. 2006), and then the progeny were crossed with Pdx-TetA
(Pdx-tTA) knock-in mice expressing tTA in the pancreas (Holland et al. 2002). Resultant PdxtTA;TetO-MyrAKT1 transgenic mice were identified by genotyping (Figure 12).
Transgenic Lox-Stop-Lox (LSL) KRasG12D (Jackson et al. 2001) and Pdx-Cre (Gu et al.
2002) mice were expanded, and these parental mice were mated to obtain compound mice
expressing Pdx-Cre–activated KRasG12D. Resultant Pdx-Cre;LSL-KRasG12D were then mated
to Pdx-tTA;TetO-MyrAKT1 mice to generate pancreatic-specific active mutant KRasG12D,
active AKT1Myr, compound mutant AKT1Myr/KRasG12D mice or non-mutant littermates. The
progeny were genotyped and littermates were followed phenotypically to determine if there is
cooperation between mutant active KRasG12D and AKT1Myr to accelerate malignancy and/or
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metastasis and to establish a potentially clinically relevant pancreatic tumor model useful for future
preclinical studies to test novel targeted therapies.
Figure 8 shows age in weeks when a carcinoma was detected in mice with compound
AKT1Myr/KRasG12D relative to mice with KRasG12D mutant alone. Kaplan-Meier curves
(GraphPad Prism 5, San Diego, CA) were used to calculate median tumor detection at 54 weeks
in AKT1Myr/KRasG12D mice compared to 74 weeks in KRasG12D mice. At the median 54-week
time point for AKT1Myr/KRasG12D mice, 11 of 22 mice examined had developed early to full
pancreatic carcinoma. In comparison, only one early carcinoma and one PDAC were found in
seven age-matched KRasG12D mice, and tumor progression to PDAC was significantly delayed
in a subset of KRasG12D mice until approximately 15 months of age. Overall, the number of mice
found with early carcinoma to PDAC was 14 of 30 AKT1Myr/KRasG12D and 13 of 29 KRasG12D
mice, even though AKT1Myr/KRasG12D mice declined in health earlier and could not be aged as
far as KRasG12D mice. Four metastatic tumors were found in AKT1Myr/KRasG12D mice at 8 to
12 months of age compared to 0 metastatic tumors in KRasG12D (Table 1). In contrast, littermates
that were AKT1Myr mice had a tendency to develop islet carcinomas (Figure 13), rather than ductal
carcinomas, at a mean latency of 75 weeks in 6 of 24 mice. Because of the predominant islet
carcinoma lineage in the AKT1Myr subset, these mice were not characterized further in the context
of this PDAC study.

Double AKT1Myr/KRasG12D Mice at ≤ 1 Year of Age Exhibit PanINs and PDACs
In a separate experiment, compound mutant AKT1Myr/KRasG12D mice were then studied
within 12 months for the frequency of PanINs and metastatic PDACs. Nearly 77% of compound
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AKT1Myr/KRasG12D mice aged ≤ 1 year exhibited high-grade PanINs and or PDACs (Table 2).
Four of 17 mice developed PDACs. This is consistent with the results from the Kaplan-Meier
study, which showed median histologic detection of malignant tumor progression at 54 weeks in
AKT1Myr/KRasG12D mice (Figure 8).

AKT Pathway Effector Proteins Are Activated in Early PanINs and Metastatic PDACs
Immunohistochemistry using phosphorylation-specific antibodies depicted abundant AKT
pathway signaling in PanINs and metastatic PDACs (Figure 9). Pathway markers, including
phospho-AKT, phospho-mTor, and phospho-p70S6 kinase were found in the pancreas of both
AKT1Myr/KRasG12D (Figure 9A) and KRasG12D mice (Figure 9B). A possible mechanism may
be increased proliferation, as detected by Ki67 staining, in the PanINs shown in Figure 9A (see
Figure 14). Metastatic PDACs in AKT1Myr/KRasG12D mice exhibited ascites and metastasis to
liver or other abdominal sites, with abundant levels of phospho-AKT and elevated levels of
phospho-mTor and phospho-p70S6 kinase at the metastatic sites (Figure 9C).

Markers of Tissue Remodeling in the Pancreas of Mice Undergoing Progression to PDAC
Alcian Blue and Muc-4 staining, markers of mucin expression, were evident in the
pancreatic ducts found in proximity to PDACs. Importantly, Muc-4 is a mucin that has been
implicated as a marker of pancreatic ductal tissue transformation in human PanINs and PDACs
(Swartz et al. 2002). In mice, Muc-4 has also been shown to correlate with the progression of
pancreatic cancer from PanIN lesions to PDAC (Rachagani et al. 2012). Staining for Muc-4 was
found in ductal regions, as well as some acinar regions of AKT1Myr/KRasG12D mice with PDAC
(Figure 10).
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Similarly, activation of pancreatic stellate cells near centroacinar cells has been implicated
as contributing to desmoplastic or fibrotic areas in PDACs and frequently expresses α-SMA (Yen
et al. 2002). Recurrent staining for trichrome and α-SMA was found around the acinar regions of
pancreatic tissue with PDAC and PanIN lesions in AKT1Myr/KRasG12D mice (Figure 10A,
representative age 7 months) and KRasG12D mice (Figure 10B, representative age 12 months).
Trichrome stain revealed mild to moderate fibrosis, reminiscent of desmoplasia. Intensity of
trichrome stain was variable, as depicted by green-blue staining (Figure 15) in a 12-month-old
AKT1Myr/KRasG12D mouse. α-SMA staining was frequently detected in pancreatic acini
exhibiting a myoepithelial distribution pattern.

Tumor Cells from Double Mutant Mice Exhibit High AKT Phosphorylation and Loss of Tumor
Suppressors Known to be Important in Human Pancreatic Tumor Progression
Cell cultures were derived from three KRasG12D mice diagnosed with PanINs at age 10
to 11 months and also three AKT1Myr/KRasG12D mice with preneoplastic lesions and/or PDACs
at age 7 to 11 months of age. Western blot analysis revealed high levels of phosphorylated AKT
in low passage cell cultures from AKT1Myr/KRasG12D mice, relative to cells from KRasG12D
mice and two human PDAC cell lines (Figure 11A). For mouse tumors cells, p53 tumor suppressor
protein was retained in all cases. Tumor suppressor p16Ink4a protein expression was frequently
downregulated in the cell cultures, with complete loss of p16Ink4a in one of the
AKT1Myr/KRasG12D PDAC cell cultures. P19Arf protein expression was also difficult to detect,
and p19Arf protein was absent in the same PDAC cell culture with loss of p16Ink4a. Genomic
PCR confirmed biallelic loss of the overlapping genes p16Ink4a and p19Arf, which reside at the
Cdk2na locus, in tumor cells from an AKT1Myr/KRasG12D mouse that developed PDAC (Figure
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11B). Such homozygous losses of CDNK2A are common in human PDACs. Moreover, a
tumorigenicity study with this same PDAC tumor cell culture revealed that it was capable of
forming tumors in syngeneic mice without the mutant alleles at ~ 3 weeks after the orthotopic
injection of 1 × 106 cells into mouse pancreas (Figure 16).

Discussion
Pancreatic mouse models targeting genes known to be mapped to the histologic and genetic
profile of PDACs have been used to test cooperativity with KRas mutations, as reviewed elsewhere
(Herreros-Villanueva et al. 2012). In most cases, the combination of the predisposing KRas
mutation with loss of tumor suppressors, such as p16Ink4a or p53, greatly accelerates malignancy
such that mice frequently die within a few months. In humans, according to 2014 American Cancer
Society projections, the median age of pancreatic cancer detection is 71 years old and increases
with

age

(http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-

038828.pdf). Moreover, in humans, the progression of PanINs to PDAC probably takes more than
a decade to develop (Yachida et al. 2010). Thus, the rapid onset of pancreatic disease in compound
KRas/tumor suppressor knockout mice has limited utility for studies relevant to disease in the
elderly and with other non-genetic factors that contribute to disease and treatment. The overall
objective of the current in vivo study was to combine two oncogenic changes important for cancer
progression to accelerate tumorigenesis, while maintaining a time frame that would align more
closely with the physiological progression observed in the human disease.
Recently, E17K mutations in the AKT1 pleckstrin homology domain have been found in
human pancreatic intraductal papillary mucinous neoplasms (3 of 36), along with activating
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mutations in PI3K or loss of PTEN (Garcia-Carracedo et al. 2013). AKT1 E17K mutations were
not found in a previous study of PDACs (Bleeker et al. 2008), although the number of cases
examined (12) was small. Thus, the role of the AKT1 E17K mutation is still being defined and
may be context dependent. As proof of principle, we used an AKT1 construct with an N-terminal
myristoylation sequence (MyrAKT1), one of the oldest known constitutively active mutants of
AKT1 (Andjelković et al. 1997), to directly test the experimental in vivo role of constitutively
active AKT1Myr in the progression from PanINs to PDAC. In contrast to the E17K mutation, the
myristoylation sequence is well documented as directing AKT to the plasma membrane and
facilitating constitutive activation (Kohn et al. 1996), which in turn has been shown to be important
for oncogenic transformation (Sun et al. 2001).
In addition to active mutant AKT1, loss of the PTEN tumor suppressor protein or
constitutive activation of receptor-mediated or upstream PI3K signaling is another means for
constitutive activation of AKT isoforms (She et al. 2005; She et al. 2008). Moreover, it has been
suggested that loss of PTEN function and active mutations of KRas may converge to facilitate
tumor growth (Ogawa et al. 2005). In terms of previous mouse models of pancreatic cancer, it has
been suggested that variations in phenotypes between Pdx-Cre–activated KRasG12D and PdxCre;Ptenlox/lox mice may be attributed to differences in the relative expression of KRas and Pten
within centroacinar and duct cells. Previously, it was shown that all mice with KRasG12D
activation and Pten homozygous deletion succumb to cancer by 3 weeks of age, and compound
mutant mice for KRasG12D and heterozygous for Ptenlox/+ show accelerated acinar-to-ductal
metaplasia, PanINs, and PDAC within a year (Hill et al. 2010). The high levels of phosphorylated
effectors downstream in the Pten/AKT signaling cascade may be a mechanism to facilitate the
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ductal pancreatic tumor progression. In addition, Pdx-Cre;Pten−/− pancreatic knockout mice were
shown to display progressive replacement of the acinar cells, with ductal structures that expressed
mucins.
In the AKT1Myr/KRasG12D model presented here, tumor onset was accelerated compared
to that observed in the KRasG12D model. The first Kaplan-Meier analysis showed that
AKT1Myr/KRasG12D mice aged 8 to 16 months had the greatest incidence of early or late
carcinomas (12/23 or 52% of the mice in this age group), with 4 metastatic tumors, compared to
only 5 of 14 (35%) of the KRasG12D mice (Figure 8 and Table 1). Overall, only two KRasG12D
mice with metastasis were found at > 16 months of age when more tumors were found in the
KRasG12D group and at an age when only one AKT1Myr/KRasG12D could be analyzed. The
second AKT1Myr/KRasG12D study used re-derived mice when the colony was transferred to a new
institution. It focused on mice aged to 1 year (Table 2) and was consistent with the Kaplan-Meier
analysis in finding PanINs and PDAC, some with metastasis at less than 1 year of age. We cannot
rule out other factors that may contribute to the decline of health in the AKT1Myr/KRasG12D mice,
and these factors may come to light as we start analyzing the role of the AKT1Myr construct in
facilitating tissue changes by using the doxycycline-off inducible AKT1Myr construct in future
studies.
Here, we report that PDAC formation in the compound transgenic AKT1Myr/KRasG12D
mice mimicked a subset of histologic alterations found in human pancreatic tumor progression,
KRasG12D and perhaps KRasG12D/Ptenlox/+ deficient mice. Consistently, we found
phosphorylation of AKT and downstream mTor kinase and p70S6 kinase in AKT1Myr/KRasG12D
mice, both in early lesions and in metastatic PDACs (Figure 9). There also was extensive
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remodeling of both ductal and acinar components, as evident by increased mucin, α-SMA, and
nearby fibrosis. Similar to other reports implicating Muc-4 as a marker of pancreatic ductal tissue
transformation in human PanINs and PDACs (Swartz et al. 2002), Muc-4 expression and overall
Alcian Blue for both neural and acidic mucins was increased in the ductal components in PanINs
and in focal regions of the PDACs in these mice (Figure 10). Similarly, moderate to abundant
collagen in the stroma was evident in disrupted acinar regions and around abnormal ducts.
To examine common genetic changes that are known to be important in the pancreatic
tumor progression cascade, tumor cells were derived from the mice predisposed to pancreatic
tumor progression and examined for down-regulation or occasional biallelic loss of tumor
suppressor genes commonly implicated in PDAC. Overall, the establishment of cell cultures from
the KRasG12D mice was challenging, perhaps in part due to the inefficiency of developing full
PDACs until mice had reached an advanced age. A limited number of primary cultures from
AKT1Myr/KRasG12D PDACs were established. Similar to human pancreatic tumors, genomic
PCR and Western blot analysis confirmed biallelic loss of p16Ink4a and p19Arf tumor suppressor
gene expression in representative PDAC cells from an AKT1Myr/KRasG12D mouse (Figure 11).
Moreover, staining for H&E and immunohistochemistry against cytokeratin 17/19 detected tumors
from AKT1Myr/KRasG12D PDAC cells when they were orthotopically re-injected into the
pancreas of a syngeneic mouse to show tumorigenic potential (Figure 16).
Collectively, compound AKT1Myr/KRasG12D mice exhibited accelerated PDAC
development compared with KRasG12D mice, and the tumors in AKT1Myr/KRasG12D mice
showed histologic and genetic alterations that recapitulate those found in human pancreatic
progression. Thus, this mouse model is likely to be of importance for preclinical testing of novel
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therapeutics targeting KRas and/or PI3K/AKT signaling in pancreatic cancer. Future analysis of
the AKT1Myr/KRasG12D mouse model is expected to elucidate in vivo contexts in which AKT1
and KRas oncogenes interact in the pancreatic microenvironment to better facilitate treatment and
overcome poor patient prognosis currently associated with this deadly disease. In particular, we
suggest that the model may have added value for chemoprevention studies to block tumor
progression at the PanIN or early carcinoma stage, perhaps before a stage where there is excessive
desmoplastic damage and fibrosis.
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Figures and Tables

Table 1: Mice with Pancreatic Carcinomas for Kaplan-Meier Analysis

<8 months
AKT1Myr/KRasG12D 1/6 mice*

8 to 16 months

>16 months

Total

12/23 mice

1/1 mouse (0

14/30

(four

metastasis)

metastases)
KRasG12D

5/14 mice (0

8/15 mice (two

metastasis)

metastases)

13/29†

⁎ AKT1Myr/KRasG12D mice were collected at < 8 months primarily because of weight loss,
although KRasG12D mice did not exhibit comparable issues.
†Other pathologies in aged KRasG12D mice ≥ 12 months of age included lymphomas,
hepatocellular carcinoma, and lung adenocarcinoma; a lung adenocarcinoma was found in an agedmatched AKT1Myr/KRasG12D mouse.
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Table 2: Representative Histology of AKT1Myr/KRasG12D Mice up to 1 Year of Age
Age
Mouse ID

Genotype

(Wks)

PanIN Low Grade

PanIN High Grade

173

Akt/Ras

13.6

X

X

524

Akt/Ras

20.6

X

179

Akt/Ras

27.7

X

505

Akt/Ras

29.1

X

547

Akt/Ras

29.4

X

X

192

Akt/Ras

31.1

X

X

195(562)

Akt/Ras

31.1

X

X

160

Akt/Ras

31.9

X

161

Akt/Ras

31.9

X

X

165

Akt/Ras

31.9

X

X

139

Akt/Ras

38.4

X

157

Akt/Ras

46.4

X

533

Akt/Ras

43.1

X

X*†

9C

Akt/Ras

46.4

X

X*

167

Akt/Ras

48.4

X

106

Akt/Ras

50.9

177-2

Akt/Ras

52.9

X

X

PDAC

Xʘ

Xʘ

X
X

12 of 17

13 of 17

4 of 17

Fibroadenomatous lesions are also found in 173, 524, 547, 160, 161, 165, 157, 106, and 177-2.
Cystic papillary lesion, early cystoadenoma, and intraductal papillary tumor are found in 524, 192,
and 167, respectively. (* metastasis, †carcinomatosis, ʘpapillary)
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Figure 8: Tumor Latency in AKT1Myr/KRasG12D versus KRasG12D mice.*

AKT1Myr/KRasG12D mice (broken line) developed pancreatic tumors (PDACs) at a faster rate
than KRasG12D mice (solid line). Curves were significantly different with a P value < .0001 by
log rank (Mantel-Cox) or Gehan-Breslow-Wilcoxon tests (GraphPad Prism 5).
*Figure assembled by corresponding author, Dr. Deborah D Altomare, and pathologist, Dr. Andres
Klein-Szanto, at Fox Chase Cancer Center.
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Figure 9: Activation of the AKT/mTor/S6K Pathway in Pancreatic Tumor Progression.*

The panels show representative early ductal pancreatic lesions, similar to human low-grade
PanINs, with strong activation (brown DAB stain) for phospho-AKT, phospho-mTor, and
phospho-p70S6 kinase in PanINs of (A) AKT1Myr/KRasG12D and (B) KRasG12D mice (40 ×
objective). (C) Immunohistochemical staining of primary PDAC and metastatic specimens from a
~ 43-week-old AKT1Myr/KRasG12D mouse for phospho-AKT, phospho-mTor, and phosphop70S6 kinase and cytokeratin 17/19; a set of panels corresponding to PDAC metastasis to liver
(10 × objective and a scale bar corresponding to 200 μm, with boxed-in close ups from the 40 ×
objective and a scale bar of 50 μm). In the metastasis panels, L = liver and T = tumor. Images were
acquired using a Leica DM 2000 microscope with a digital DFC 295 camera.
*Figure assembled by co-first authors, Toya Albury-Warren and Veethika Pandey.
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Figure 10: Pancreatic histologic alterations in AKT1Myr/KRasG12D and KRasG12D mice.*

The panels from (A) AKT1Myr/KRasG12D and (B) KRasG12D mice show staining of
representative pancreatic tissues. Sections showed staining for H&E, Alcian Blue staining of ducts
for detection of mucin (dark blue), Muc-4 (brown color) in areas of ducts, trichrome stain of red
acinar cells, and green-blue collagen-rich fibrotic areas of the PDAC tumor and α-SMA marker
(brown color) in areas of acinar cells near fibrotic regions. Boxed-in highlighted areas (10 ×
objective, scale bar of 200 μm) were magnified for a focal view with the 40 × objective (scale bar
of 50 μm).
*Figure assembled by co-first author, Sarah Gitto.
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Figure 11: Phospho-AKT and tumor suppressors in mouse and human pancreatic tumor cells.*

(A) (Left) Representative Western blots from each of three KRasG12D (mouse numbers 190, 148,
and 117) and three AKT1Myr/KRasG12D (mouse numbers 505, 9C, and 533) tumor cell cultures
analyzed for expression of total AKT, phospho-AKT (Ser473), and tumor suppressor genes p53,
p16Ink4a, and p19Arf. Actin is a loading control. (Right) Representative human pancreatic tumor
cell lines run adjacent to mouse tumor cells showing relative amount of total AKT, phospho-AKT
(Ser473), and actin. (B) Genomic DNA PCR showing retention or loss of Tp53, p16Ink4a, or
p19Arf.
*Figure assembled by co-first author, Veethika Pandey, and author Lina Spinel.
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Figure 12: General construct scheme for generating genetically engineered mice.
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Figure 13: Representative islet carcinomas from aged AKT1Myr mice.
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Figure 14: Ki67 immunohistochemistry for representative PanINs shown in Figure 2, A and B.

48

Figure 15: Representative α-SMA and trichrome staining of pancreas from a 12-month-old
AKT1Myr/KRasG12D mouse.
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Figure 16: Representative H&E and cytokeratin 17/19 of orthotopically injected
AKT1Myr/KRasG12D PDAC cells (from mouse 533) into a syngeneic mouse that lacked
corresponding mutant alleles.

Primary cell culture derived from a representative AKT1Myr/KRasG12D mouse (histology shown
in Fig 2c) was tested for tumorigenicity. One million cells suspended in 50μL PBS were
orthotopically injected into the head of the pancreas of wild-type syngeneic mice using 28 ½ G
syringes. Tumor growth was monitored by ultrasound imaging and detectable tumor growth was
seen 1 week post tumor cell inoculation. The representative tumor was collected at 3 weeks.
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CHAPTER 3:
PREDIABETES LINKED TO EXCESS GLUCAGON IN TRANSGENIC
MICE WITH PANCREATIC ACTIVE AKT1
Introduction
AKT, a serine/threonine kinase, is downstream of phosphatidylinositol 3-kinase (PI3K)
and growth factor receptors (e.g., epidermal growth factor receptor, EGFR), and is a hallmark
signaling protein predominantly recognized for regulation of cell survival, growth, and
proliferation. AKT signals through the phosphorylation and subsequent activation or inhibition of
downstream substrates, such as mammalian target of rapamycin complex 1 (mTORC1) or
glycogen synthase kinase 3 beta (GSK-3β), respectively (Hemmings & Restuccia 2012). AKT
hyperactivation in various cancers has been studied (Altomare & Testa 2005; Cheung & Testa
2013), while its role in glucose metabolism has been noted, but comparatively overlooked until
analysis of AKT isoform knockout mice.
Although analogous in structure, AKT isoforms (AKT1, AKT2, and AKT3) are encoded
by three different genes, which are differentially expressed in tissues and have varying functions
(Hay 2011). While AKT1 is ubiquitously expressed in mammalian tissues, it was initially deemed
unnecessary for glucose homeostasis as AKT1 knockout mice (AKT1-/-) have impaired fetal and
adulthood growth, but normal glucose tolerance and insulin signaling (Cho et al. 2001). AKT3 is
primarily expressed in the brain and was also reported unnecessary for glucose homeostasis with
AKT3-/- mice exhibiting reduced brain size and weight, but normal glucose regulation (Tschopp
et al. 2005). In contrast, AKT2 is highly expressed in insulin responsive tissues and has been
identified as a primary regulator of glucose metabolism, as AKT2 knockout mice (AKT2-/-) are
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prediabetic with insulin resistance, hyperinsulinemia, and glucose intolerance (Cho et al. 2001;
Garofalo et al. 2003).
A role for AKT1 in glucose homeostasis became evident with the metabolic analysis of
compound isoform knockout mice (Chen et al. 2009). Similar to AKT2-/- mice, AKT1+/+AKT2-/AKT3-/- mice were mildly diabetic suggesting that the loss of AKT3 was inconsequential.
Conversely, haplodeficiency of AKT1 in AKT2-/- mice resulted in a more severe diabetic
phenotype, characterized by fed and fasted hyperglycemia, glucose intolerance, insulin resistance,
and hyperinsulinemia. Additional crosses of AKT1+/-AKT2-/- mice with mice haplodeficient for
tumor suppressor phosphatase and tensin homolog (PTEN+/-), an upstream regulator of AKT
activation, significantly improved glucose homeostasis, and demonstrated the compensatory
nature and importance of AKT1, contrary to previous reports (Cho et al. 2001). Although AKT1
hyperactivation has been frequently observed in pancreatic cancers (Schlieman et al. 2003;
Missiaglia et al. 2010), there are limited studies regarding AKT1 hyperactivation and glucose
homeostasis, except for attempts to improve the success rates of human islet transplantation
therapy for diabetic patients (Bernal-Mizrachi et al. 2001; Tuttle et al. 2001; Kushner et al. 2005;
Stiles et al. 2006;). Hyperactivation of AKT1 in pancreatic β–cells, via PTEN deletion (Kushner
et al. 2005; Stiles et al. 2006) or in mice with a myristoylated AKT1 (Bernal-Mizrachi et al. 2001;
Tuttle et al. 2001) under expression of a rat insulin promoter (RIP) led to hypoglycemia,
hyperinsulinemia, and improved glucose tolerance, due to increased β–cell mass, size, and
proliferation.
We recently characterized aged mice with myristoylated, membrane-bound AKT1
(AKT1Myr) expressed using the Pdx promoter (Albury et al. 2015) and found that ~25% of mice
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developed islet cell carcinomas after one year of age. Here we report that this strain of mice exhibit
non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by 20 weeks of age, thus
presenting a potentially unique opportunity to study the mechanistic cross-talk between diabetes
and cancer. We show that the pre-diabetic phenotype can be attributed to the AKT1Myr transgene,
as it is tetracycline-regulatable, and down regulation of the AKT1Myr transgene reduced the nonfasted and fasted hyperglycemia to wild type levels. Collectively, metabolic characterization of
the AKT1Myr mice revealed a novel glucagon-mediated mechanism by which AKT1
hyperactivation affects glucose homeostasis.

Materials and Methods
Genetically Engineered Mice
All mice were housed and handled according to protocols approved by the University of
Central Florida (UCF) Institutional Animal Care and Use Committee at the AAALAC accredited
UCF Lake Nona Animal Facility. Transgenic mice with activation of AKT1 (Pdx-tTA;TetOMyrAKT1) were mated as previously described (Albury et al. 2015). At 3 weeks, the pups were
weaned and tail snipped for DNA extraction and genotyping, as previously described (Albury et
al. 2015). Mice with TetO-MyrAKT1, but lacking the knock-in Pdx-tTA, were classified as
normal or wild-type litter mates. Mice with Pdx-tTA and TetO-MyrAKT1 were classified as
AKT1Myr mice having constitutively active AKT1 in the pancreas. Litters were placed on a
standard control diet or a doxycycline diet (BioServ, Frenchtown, NJ), which shuts off AKT1Myr
transgene expression. All mice were euthanized according to American Veterinary Medical
Association guidelines.
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Genotyping Analysis
Primers for polymerase chain reactions (PCR) for AKT1Myr mice were previously
described (Albury et al. 2015). AKT2KO mice were obtained from J. R. Testa (Fox Chase Cancer
Center, Philadelphia, PA), and PCR primers detected the presence of wild-type or knockout AKT2
(5’-GATGAACTTCAGGGTCAGCTT-3’;

5’-AGAGCTTCAGTGGATAGCCTA-3’;

5’-

TCTCTGTCACCTCCCCATGAG-3’).

Histological Analysis
Pancreatic tissue was fixed in 10% neutral buffered formalin (Surgipath Leica, Buffalo
Grove, IL) and embedded in paraffin for sectioning and processing as previously described
(Albury et al. 2015).

Slides were stained for hematoxylin and eosin (Surgipath) or

immunohistochemistry using the Polymer Refine Detection reagents (Leica) on the Bond-Max
immunostainer (Leica). Antigen retrieval was optimized using sodium citrate (pH 6) or EDTA
(pH 9) buffers (Leica). The following antibodies were used: phospho-AKT Ser473 (GeneTex,
Irvine, CA), also phospho-mTor Ser2448, phospho-S6 Ser235/236, glucagon, and insulin (all from
Cell Signaling Technology, Danvers, MA). All slides processed on the immunostainer were run
with a negative control, which was treated with antibody diluent instead of the primary antibody,
to ensure antibody specificity. Images were taken using a Leica DM 2000 microscope with 5X,
10X, or 40X objectives. Islet size was measured in the whole pancreas of three mice per genotype.
The mice selected had no significant lesions (NSL) at the time of necropsy, as described by a
pathologist. The pancreas was sectioned into 5μm sections and every 25th section was H&E
stained. A total of 50 islets from three sections were analyzed per mouse. Islet diameter was
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determined using measuring tools available on an Axio Imaging System (Zeiss, Oberkochen,
Germany).

Blood Glucose Measurement
Blood glucose levels were measured using a Contour glucometer (Bayer, Mississauga,
Ontario, Canada) at weaning, 5-, 7-, 9-, and 12 weeks. Weaning was at 3 weeks of age. Blood
glucose levels were measured randomly, between 9 AM and 10 AM, or after an overnight fast.

Glucose Tolerance Test
Mice were fasted overnight, weighed (g), intraperitoneal (IP) injected with 2g/kg Dglucose (Fisher, Waltham, MA) and blood glucose tested with a glucometer before injection, 15-,
30-, 45-, 60-, and 120 minutes after injection. Blood glucose (mg/dL) versus time (minutes) was
plotted and the area under the curve was calculated using Graph Pad Prism 5 (Graph Pad Software,
La Jolla, CA). Blood was collected, via cheek bleeds, into serum collection tubes at 0 and 45
minutes after injection. The serum was separated and stored at -80°C until analysis with Mercodia
Glucagon and Ultrasensitive Mouse Insulin ELISAs (Mercodia, Uppsala, Sweden). The HOMAIR [(fasted glucose x fasted insulin)/405] was calculated using the fasted blood glucose and fasted
serum insulin levels acquired during the glucose tolerance test (Grote et al. 2013).

Insulin Tolerance Test
Mice were fasted for 2 hours, weighed (g), IP injected with 2 IU/kg porcine insulin (Sigma,
Milwaukee, WI), and blood glucose tested with a glucometer before injection, 15-, 30-, 45-, and 60 minutes
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after injection. Blood glucose (mg/dL) versus time (minutes) was plotted and the area under the curve was
calculated (GraphPad).

Insulin Stimulation
Mice were fasted overnight, weighed (g), anesthetized using isoflurane, and injected with
porcine insulin (10 IU/kg) (Sigma) or saline via the inferior vena cava. After two minutes mice
were euthanized and the following tissues were snap frozen in liquid nitrogen: pancreas, liver,
perigonadal adipose tissue, and skeletal muscle.

Tissues were homogenized using 15 mg

Zirconium oxide beads (1.0 mm for skeletal muscle and 0.5 mm for adipose, liver, and pancreas)
with the Bullet Blender Homogenizer BBX24 (Next Advance, Averill Park, NY, USA). Proteins
were extracted for ELISA analysis for AKT, AKT (pS473), Insulin Receptor (IR), and IR
(pY1158) (all from Invitrogen, Camarillo, CA). Data was analyzed using a four parameter
algorithm to construct the best fitting curve.

Statistical Analysis
Results are reported as mean ± SEM. Comparisons were made between two and more than
two groups using unpaired or paired student’s t-tests and two-way Anova followed by student’s ttests within groups, respectively. All analysis used Graph Pad Prism 5 with significance accepted
at a P value of <0.05. Letters were used to illustrate significance as multiple groups are being
compared. Groups that do not share the same letter display a statistical significance of p<0.05.

61

Results
AKT1Myr transgenic mice have tetracycline-regulatable AKT/mTOR pathway activation in the
pancreas.
The AKT1Myr construct uses the Pdx1 promoter, which is important for pancreas
development in utero and postnatal β-cell maintenance (Holland et al. 2002), to drive the
expression of myristoylated, and therefore active AKT1 within different pancreatic cell lineages.
Expression of the AKT1Myr transgene is inhibited in the presence of the tetracycline analogue
doxycycline. Immunohistochemistry (Figure 17A), using phospho-specific antibodies, validated
increased phosphorylated or active AKT1, along with its downstream substrates mTORC1 and S6,
in the islets of AKT1Myr mice given standard feed, as compared to wild-type mice on standard feed
and doxycycline fed AKT1Myr mice. To quantify this result, protein was extracted from insulinstimulated pancreatic tissue and measured via ELISA (Figure 17B), confirming significantly
elevated (p<0.001) AKT1 phosphorylation (Ser 473), and thus activation in AKT1Myr mice versus
wild type mice. Pancreatic levels of phosphorylated AKT1 (Ser 473) were eight times greater in
AKT1Myr mice than wild type mice, while phosphorylated AKT1 levels in doxycycline fed
AKT1Myr mice were equal to those of wild type mice, confirming the ability of doxycycline to turn
off the transgene. Doxycycline treatment began at weaning and continued for 2 weeks, which
was sufficient to decrease the activation of the AKT/mTOR pathway to wild-type levels. There
was no significant difference in total AKT between groups.

Reversible, non-fasted and fasted hyperglycemia in AKT1Myr transgenic mice
At weaning, mice were tail snipped for genotyping and blood glucose tested. AKT1Myr
mice (n=10), regardless of sex (Figure 18G), had significantly higher (p<0.0001) non-fasted blood
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glucose levels at weaning than wild-type littermates (Figure 18A). Non-fasted blood glucose
levels were monitored biweekly for 9 weeks following weaning, and similarly, AKT1Myr mice had
significantly higher (p=0.0031) non-fasted blood glucose levels at 12 weeks of age compared to
wild-type mice (Figure 18A).
To confirm that the non-fasted hyperglycemia was due to the AKT1Myr transgene
expression, doxycycline was administered to mice in order to turn off the transgene. Mating cages
were arranged with half receiving standard feed and half receiving doxycycline feed for in utero
exposure. Feeding regimens were continued at weaning and non-fasted blood glucose levels were
monitored biweekly for 9 weeks. At weaning, the non-fasted blood glucose levels for AKT1Myr
mice on a standard diet were significantly higher (p<0.02) than all other treatment groups. There
was no significant difference between the AKT1Myr mice on doxycycline and the wild type mice
on either diet, and the same pattern was observed at 12 weeks (Figure 18B). With regard to
overnight fasting, 12-week AKT1Myr mice exhibited no significant difference in fasted glucose
levels (Figure 18C). However, aged AKT1Myr exhibited fasted hyperglycemia, a more severe
diabetic phenotype, by 5 months of age (Figure 18D), which was also attenuated by doxycycline
treatment. Weight (Figure 18E) and food intake (Figure 18F) did not differ among genotypes.

Glucose intolerance in AKT1Myr transgenic mice due to insulin-glucagon imbalance.
Glucose tolerance testing (GTT) was performed at 12 weeks (n=5 males) to analyze the
ability of AKT1Myr mice to clear glucose from the blood. AKT1Myr mice had a significantly higher
(p=0.0049) area under the curve (Figure 19B) compared to wild-type mice. The significantly
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elevated blood glucose levels began at 30-minutes post injection and continued for the duration of
the test, signifying glucose intolerance (Figure 19A).
Glucose intolerance in AKT1Myr mice was compared and found to be similar to the wellestablished, prediabetic AKT2 null mouse model (AKT2KO) (Figure 19C). However, serum
insulin and glucagon levels, collected via cheek bleeding, revealed significant differences between
AKT1Myr and AKT2KO mice. AKT2KO mice had significantly (p<0.02) elevated insulin levels,
which were evident before the glucose injection (0 min) and 45 minutes after the injection (Figure
19D/Table 3). When compared to wild type mice, AKT1Myr mice did not initially (0 min) have
elevated insulin levels. However, insulin levels were significantly (p=0.009) higher 45 minutes
after the injection.

Serum glucagon levels in AKT2KO mice were similar to wild type mice

(Figure 19E/Table 3).

However, AKT1Myr mice had significantly (p<0.05) elevated fasted

glucagon levels (0 min), which returned to wild type levels by the 45-minute time point. In
addition to functional differences in pancreatic α–cells, AKT1Myr mice had an altered distribution
of α–cells throughout the pancreatic islets (Figure 19F), typical of several diabetic murine models
(Bates et al. 2008; Cummings et al. 2008).

Insulin resistance in the liver of AKT1Myr transgenic mice
One week following the GTT, an insulin tolerance test (n=5 males) was performed to
analyze the sensitivity of insulin-responsive tissues in AKT1Myr mice. Area under the curve was
calculated (Figure 20A), blood glucose versus time, and was not significantly different when
comparing AKT1Myr mice and wild type mice. However, at the 15 minute time point the AKT1Myr
mice had significantly higher (p=0.035) blood glucose levels than the wild-type mice (Figure 20B).
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To further analyze insulin signaling, mice were injected with 10 IU/kg porcine insulin (n=5
males) or saline (n=5 males) via the inferior vena cava. Analysis of liver tissue revealed
significantly decreased insulin receptor (IR) phosphorylation (Figure 20C) in AKT1Myr mice,
compared to wild type mice, despite no significant difference in insulin receptor levels. There were
no differences in IR phosphorylation in adipose or muscle tissue (Figure 20D & 20E). Calculation
of the homeostatic model assessment for insulin resistance (HOMA-IR) confirmed insulin
resistance in AKT1Myr mice, as compared to wild type mice (Figure 20F).

Decreased pancreas and islet size, with aging, in AKT1Myr mice.
Pancreas size was measured upon euthanization and dissection using a digital scale (n=5)
in 12 week (Figure 21A) and 16 month (Figure 21B) old mice. The pancreas size in the young
AKT1Myr mice was not significantly different. However, the pancreas size in the aged 16 month
old AKT1Myr mice was significantly smaller (p=0.0049) than wild type mice. Islet size (n=50
islets) was also measured at 12 weeks (Figure 21C) and 16 months (Figure 21D). Islet diameter
was not significantly different in 12 week old mice, but significantly decreased (p=0.008) in 16
month old mice.

Discussion
In this study we characterized the early onset, prediabetic phenotype observed in AKT1Myr
mice and highlighted a novel mechanism by which AKT1 hyperactivation affects glucose
homeostasis. AKT1Myr mice, previously described for their aged onset islet cell carcinomas
(Albury et al. 2015), have bicistronic regulation of myristoylated AKT1 through a Pdx1-TetA and
TetO-MyrAKT1 system. This allows the expression of myristoylated, membrane-bound and thus
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activated, AKT1 in the pancreas except in the presence of doxycycline, a tetracycline analogue.
The Pdx1 promoter, which is important for pancreas development in utero and postnatal β-cell
maintenance (Holland et al. 2002), drives expression within the pancreatic progenitor cells, which
eventually give rise to the endocrine cells (islets of Langerhans), exocrine cells (acini cells), and
ductal cells of the pancreas (Hale et al. 2005). The hyperactivation of AKT1 throughout all cell
types of the pancreas distinguishes this model from other constitutively active AKT1 mouse
models, which use a rat insulin promoter (RIP) to drive expression in the β-cells (Bernal-Mizrachi
et al. 2001; Tuttle et al. 2001). Additionally, the use of different tissue specific promoters
highlights the important role of expression patterns and cellular localization for AKT function.
The novelty of the glucose deregulation in AKT1Myr mice is further elucidated when
compared to the known, prediabetic AKT2 null mouse model (AKT2KO). As previously reported,
AKT2KO mice have fasted and fed hyperglycemia beginning at 5- and 10 weeks in males and
females respectively (Garofalo et al. 2003). Male mice progress to a severe form of diabetes by 5
months of age and females remain prediabetic until 12 months of age (Cho H et al. 2001).
Conversely, AKT1Myr mice, regardless of sex, exhibited nonfasted hyperglycemia at weaning.
There was an increase in severity with time as fasted hyperglycemia was not detectable until 5
months of age. To confirm that the hyperglycemia was due to the AKT1Myr transgene expression,
doxycycline was administered to the mice to turn off the transgene. Doxycycline treatment
reduced AKT1Myr blood glucose to wild type levels, confirming that the fasted and non-fasted
hyperglycemia in AKT1Myr mice was due to AKT1 hyperactivation. Other possible contributing
factors, such as weight and food intake, were ruled out further distinguishing the AKT1Myr mice
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from the lighter AKT2KO mice (Garofalo et al. 2003) and heavier obese diabetic mouse models
(i.e. db/db, NZO, and TALLYHO mice) (Coleman 1982; Herberg et al. 1970; Kim et al. 2006).
Glucose tolerance testing was performed at 12 weeks to analyze the ability of AKT1Myr
mice to clear glucose from the blood. While both models exhibited glucose intolerance, serum
insulin and glucagon levels measured during the GTT revealed that the molecular mechanisms
driving the deregulations were different. As previously reported (Cho et al. 2001; Garofalo et al.
2003), AKT2KO mice had hyperinsulinemia which was evident before the glucose injection and
45 minutes after the injection. Ultimately, the AKT2KO mice model a classic, insulin-based
deregulation, in which early insulin resistance leads to compensatory hyperinsulinemia, and
eventually late insulin deficiency (Matthaei et al. 2000). When compared to wild type mice,
AKT1Myr mice did not have elevated fasted insulin levels.

However, insulin levels were

significantly higher 45 minutes after the injection. This increase in insulin secretion may be β-cell
compensation and occurred in response to the hyperglycemia also observed at this time point. This
suggests that the elevated blood glucose levels were not due to a lack of insulin production or
secretion, but reduced insulin sensitivity (Weir & Bonner-Weir 2004).
While insulin deregulations are well studied, glucagon deregulations have been
acknowledged but relatively ignored. Glucagon, which is secreted by pancreatic α–cells when
blood glucose levels are low, is known as the antagonist to insulin. When glucagon binds to its
receptor it activates cellular adenosine-3’-5’-cyclic monophosphate (cAMP) and protein kinase A
(PKA) signaling to induce hepatic gluconeogenesis and glycogenolysis restoring glucose
homeostasis during fasting (Moon & Won 2015). Increased PKA activity impairs glucose
stimulated insulin secretion (GSIS), which is needed to prevent the immediate secretion and
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glucose disposing action of insulin (Song et al. 2014). Serum glucagon levels in AKT2KO mice
were similar to wild type mice.

However, AKT1Myr mice had significantly elevated fasted

glucagon levels, which returned to wild type levels by the 45-minute time point, most likely due
to the surge in insulin secretion.
Fasted hyperglucagonemia, as seen in AKT1Myr mice, has been observed in diabetic
patients (Baron et al. 1987; Reaven et al. 1987; Unger et al. 1970), and linked to the manifestation
of fasted hyperglycemia and glucose intolerance.

The mechanisms behind hyperglucagonemia

are still relatively unclear, but it has been shown to result from the inadequate response of α–cells
to elevated blood glucose levels (Rizza 2010). This α–cell dysfunction leads to hepatic insulin
resistance (Basu et al. 2004), causing non-fasted hyperglycemia by preventing the suppression of
endogenous glucose production during a meal, and fasted hyperglycemia via chronically elevated
endogenous glucose production (Basu et al. 2000; Firth et al. 1986). The hyperglucagonemia
induced hepatic insulin resistance also significantly decreases hepatic glucose uptake and disposal
due to impaired glucokinase activity (Caro et al. 1995; Wajngot et al. 1991). This impaired hepatic
glucose metabolism has been identified in mild and severe diabetes patients making it an early
contributing event in the pathogenesis of diabetes, and not simply an effect (Basu et al. 2004; Bock
et al. 2007).
One week following the GTT, an insulin tolerance test was performed to analyze the
sensitivity of insulin-responsive tissues in AKT1Myr mice. AKT1Myr mice and wild type mice were
not significantly different when comparing area under the curve, suggesting an absence of insulin
resistance. However, at the 15 minute time point the AKT1Myr mice had significantly higher blood
glucose levels than the wild-type mice, suggesting there may be altered insulin signaling causing
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this delay in insulin response. Further analysis of liver tissue revealed significantly decreased
insulin receptor (IR) phosphorylation in AKT1Myr mice, compared to wild type mice, despite no
significant difference in insulin receptor levels. This decrease in IR activation explains the delay
in insulin response seen early in the ITT and the inability of AKT1Myr mice to aptly clear glucose
from the blood. Further calculation of the HOMA-IR confirmed insulin resistance in AKT1Myr
mice, as compared to wild type mice. However, at 12 weeks, this resistance is not as severe as the
resistance seen in AKT2KO mice.
Additional longevity studies must be performed to determine whether the insulin resistance
worsens with age, but analysis of pancreas and islet size suggests a gradual loss of β-cell mass.
This loss of β-cell mass, evident by a decrease in total pancreas size and islet diameter, is typically
indicative of long term insulin resistance and β-cell failure due to chronic hyperinsulinemia and
hyperglycemia (Prentki & Nolan 2006). There also appears to be an age induced increase in islet
diameter of wild type mice. This is most likely due to naturally occurring beta-cell compensation
or the presence of islet adenomas which also develop naturally in about 33% of our aged wild type
mice.
In this study we characterized the pre-tumor, prediabetic phenotype of AKT1Myr mice,
which exhibit non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by 5
months of age, regardless of sex. Based upon previous findings, this hyperglycemia is likely due
to α-cell dysfunction, specifically hyperglucagonemia. Although the mechanisms behind
hyperglucagonemia are still relatively unclear, we are proposing that AKT1Myr mice, with fasted
hyperglucagonemia, have impaired GSIS, resulting in glucose intolerance despite increased
compensatory insulin secretion. Hepatic insulin resistance, an additional factor, may exacerbate
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the problem, preventing normoglycemia via increased hepatic glucose production and decreased
hepatic glucose storage. As the fasted and non-fasted hyperglycemias are reversible when the
AKT1Myr transgene is suppressed we have attributed this diabetic phenotype to the constitutive
activation of AKT1 in the pancreas of this mouse model. Collectively, this pre-diabetic model
highlights a novel glucagon-mediated mechanism by which AKT1 hyperactivation affects glucose
homeostasis, and provides a means to better delineate molecular mechanisms contributing to
diabetes mellitus, and perhaps future association between diabetes and a subset of pancreatic
cancers.
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Figures and Tables
Table 3: The average insulin and glucagon serum levels in wild type, MYR AKT1, and AKT2
KO mice during the glucose tolerance test.
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Figure 17: AKT1Myr mice have doxycycline-regulatable AKT/mTOR pathway activation in the
pancreas.

Hyperactivation and decreased activation of the AKT/mTOR pathway in AKT1Myr mice on regular
chow diet and AKT1Myr mice on doxycycline diet, respectively, confirmed with: (A)
immunostaining of representative pancreatic tissue using phospho-AKT (Ser 473), phosphomTOR (Ser 2448), and phospho-S6 (Ser 235/236) antibodies (40X objective; Scale bar-50μm);
and (B) analysis of protein from pancreatic tissue using a phospho-AKT1 (Ser 473) ELISA. Twoway ANOVA followed by student’s t-tests within groups were used to analyze the data. Data
represented as mean ± SEM (n=5). All phospho-AKT1 measurements were normalized to their
total AKT measurements. Abbreviations: WT – wild type mice; Reg-regular chow diet; Dox doxycycline diet. Letters were used to illustrate significance as multiple groups are being
compared (see materials and methods for explanation).
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Figure 18: AKT1Myr mice have a reversible, fasted and non-fasted hyperglycemia.

Blood glucose levels were measured with a glucometer (A) at weaning (p<0.0001) and at 12 weeks
(p=0.0031). Weaning occurred at 3 weeks of age. To determine if the hyperglycemia exhibited
at weaning was reversible, breeder mice were placed on a doxycycline diet to expose the pups in
utero. Blood glucose levels were then measured (B) at weaning (p<0.02) and at 12 weeks
(p≤0.003). Mice were fasted overnight (16 hours) to determine fasted blood glucose levels (C) at
12 weeks and (D) at 20 weeks (p<0.005). (E) Weight was measured at weaning. At 12 weeks, mice
were housed individually and (F) food intake was measured daily for four days by weighing the
food in the cage. Blood glucose levels, measured at weaning, were used to identify (G) sex
differences. Two-way ANOVA followed by student’s t-tests within groups were used to analyze
the data for figures A-E and G. Unpaired student’s t-test was used for figure F. N=10 for figures
A-G except D (n=5). Abbreviations: Wks - week. Letters were used to illustrate significance as
multiple groups are being compared (see materials and methods for explanation).
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Figure 19: Glucose intolerance in AKT1Myr mice due to insulin-glucagon imbalance.

Glucose tolerance testing (n=5) was performed at 12 weeks comparing: (A) wild type (WT) and
AKT1Myr (MYR AKT1) mice and (C) WT, MYR AKT1, and AKT2-/- (AKT2 KO) mice (*
indicates p<0.05). (B) Area under the curve. Data represented as mean ± SEM (p=0.0049). Blood
was collected, via cheek bleeds, at the 0- and 45-minute time points to analyze serum (D) insulin
and (E) glucagon levels using ELISAs. Insulin and glucagon values are also provided in Table 3.
(F) Immunostaining of pancreatic tissue using insulin and glucagon antibodies (Objective 40X;
Scale bar-50μm). Unpaired student’s t-tests were used to analyze differences in area under the
curve and the glucose tolerance test time points. Two-way ANOVA followed by student’s t-tests
within groups were used to analyze the data for figures D-E. Letters were used to illustrate
significance as multiple groups are being compared (see materials and methods for explanation).
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Figure 20: Insulin resistance in the liver of AKT1Myr mice.

One week following the GTT, (B) an insulin tolerance test was performed (n=5). (A) Area under
the curve. Data represented as mean ± SEM (p<0.04). To analyze insulin signaling, mice were
insulin stimulated. Two minutes after injection the mice were euthanized and the pancreas, (C)
liver, (D) adipose tissue, and (E) skeletal muscle were collected, protein extracted, and analyzed
with insulin receptor (IR) Total and IR (pY1158) ELISAs. All phospho-IR measurements were
normalized to their total IR measurements. (F) Homeostatic model assessment for insulin
resistance (HOMA-IR) was calculated using the following measurements from the GTT: (fasted
glucose x fasted insulin)/405. Data represented as mean ± SEM. Unpaired student’s t-tests were
used to analyze differences in the insulin tolerance tests time points. One-way ANOVA followed
by student’s t-tests within groups were used to analyze the data for figures A and C-F. Letters
were used to illustrate significance as multiple groups are being compared (see materials and
methods for explanation).
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Figure 21: Decreased pancreas and islet size, with aging, in AKT1Myr mice.

Pancreas size was measured upon euthanization and dissection using a digital scale (n=5) in (A)
12 week and (B) 16 month (p=0.0049) old mice. Islet size (n=50 islets) was also measured at (C)
12 weeks and (D) 16 months (p=0.008). Islet diameter was determined analyzing H&E stained
sections through Axio Imaging Software. Unpaired student’s t-tests were used to analyze figures
A-D. Data represented as mean ± SEM. Letters were used to illustrate significance as multiple
groups are being compared (see materials and methods for explanation).
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CHAPTER 4:
OVERT DIABETES IN TRANSGENIC MICE WITH CONSTITUTIVELY
ACTIVE AKT1 AND MUTANT KRASG12D IN THE PANCREAS
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common cancer largely due
to late diagnosis. At diagnosis, which is typically 71 years of age, 85% of PDAC patients are
inoperable due to local and distant metastasis. Drug treatments are typically ineffective at this
advanced stage and the average survival rate is four to six months. Over the last 30 years PDAC
incidence has been relatively stable (1 to 10 per 100,000 people). However, population changes,
primarily the aging of 76.4 million baby boomers, are expected to thrust pancreatic cancer from
the ninth to the second leading cause of cancer-related deaths within the next 15 years (Ryan et al.
2014). It is vital that we quickly identify an effective, noninvasive, and cost efficient early
detection strategy, such as a biomarker, as clinical testing can take an estimated 7.9 years (Rahib
et al. 2014).
As early as the 1900s a relationship between diabetes and pancreatic cancer has been
proposed. Based upon experimental and clinical evidence, there are two prevailing theories: (1)
long-term diabetes induces pancreatic cancer and (2) new onset diabetes is an early marker for
pancreatic cancer. With 80% of PDAC patients suffering from hyperglycemia or diabetes prior to
diagnosis, this has potential to serve as a viable early detection strategy (Wang et al. 2003).
However, it is essential that the molecular mechanisms behind this association be understood. It
would be difficult to study this association in humans, primarily because PDAC is asymptomatic
until it reaches an advanced stage making it difficult to identify study participants. Moreover, it
is challenging to perform retrospective studies as blood and/or tissue collections are needed up to
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seven years prior to diagnosis. Additionally, we are currently unable to distinguish Type 2
Diabetes (T2D), which is common in the general population, from PDAC associated diabetes,
which is less common. Despite these complications there are many unanswered questions and
further basic research is required (Pannala et al. 2009; Bao et al. 2011).
Human PDAC progression is initiated by activation mutations of the KRas oncogene. This
leads to additional molecular changes, such as activation of the AKT oncogene, which drives
PDAC progression and tumor formation (Ryan et al. 2014). By mating transgenic mice with
activation of KRas (Pdx- Cre;LSL-KRasG12D) and mice with activation of AKT1 (PdxtTA;TetO-MyrAKT1) we were able to produce mice with activation of both oncogenes
(AKT1Myr/KRasG12D). These mice accurately mimic the human PDA progression molecularly,
structurally, and temporally. Additionally, they exhibit a pre-tumor diabetic phenotype at 3 weeks
of age, including random and fasted hyperglycemia.

By thoroughly studying our

AKT1Myr/KRasG12D mouse model we can identify key pre-tumor molecular events that induce
metabolic changes, distinguish PDAC associated diabetes from T2D, and identify an early
biomarker. This will ultimately lead to earlier pre-metastatic detection, effective drug treatment,
and increased PDAC survival.
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Materials and Methods
Genetically Engineered Mice
All mice were housed and handled according to protocols approved by the University of
Central Florida (UCF) Institutional Animal Care and Use Committee at the AAALAC accredited
UCF Lake Nona Animal Facility. Transgenic mice were mated, weaned, and tail snipped for DNA
extraction and genotyping as previously described in chapter 2 and 3 materials and methods. Mice
with TetO-MyrAKT1, but lacking the knock-in Pdx-tTA, were classified as normal or wild-type
litter mates. Mice with Pdx-Cre;LSL-KRasG12D were classified as KRasG12D. Mice with PdxtTA, TetO-MyrAKT1, and Pdx-Cre;LSL-KRasG12D were classified as AKT1Myr/KRasG12D.
Litters were placed on a standard control diet or a doxycycline diet (BioServ, Frenchtown, NJ),
which shuts off AKT1Myr transgene expression. All mice were euthanized according to American
Veterinary Medical Association guidelines.

Blood Glucose Measurement
Blood glucose levels were measured, using a glucometer, as previously described in
chapter 3 materials and methods.

Glucose and Insulin Tolerance Test
For glucose tolerance testing mice were fasted overnight, weighed (g), intraperitoneal (IP)
injected with 2g/kg D-glucose and blood glucose tested with a glucometer before injection, 15-,
30-, 45-, 60-, and 120 minutes after injection. Blood was collected, via cheek bleeds, into serum
collection tubes at 0 and 45 minutes after injection. The serum was separated and stored at -80°C
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until analysis with Mercodia Glucagon and Ultrasensitive Mouse Insulin ELISAs. For insulin
tolerance testing mice were fasted for 2 hours, weighed (g), IP injected with 2 IU/kg porcine
insulin, and blood glucose tested with a glucometer before injection, 15-, 30-, 45-, and 60 minutes
after injection. For both tests, GTT and ITT, blood glucose (mg/dL) versus time (minutes) was
plotted and the area under the curve was calculated using GraphPad. Manufacturer information
for all products were provided in chapter 3 materials and methods.

Statistical Analysis
All statistical analysis were described in chapter 3 materials and methods.

Results
Reversible, non-fasted and fasted hyperglycemia in AKT1Myr/KRasG12D transgenic mice
At weaning, mice were tail snipped for genotyping and blood glucose tested.
AKT1Myr/KRasG12D (AKTRAS) mice (n=10), regardless of sex (Figure 22C), had significantly
higher (p<0.0001) non-fasted blood glucose levels at weaning than wild-type littermates (Figure
22A). Non-fasted blood glucose levels were monitored biweekly for 9 weeks following weaning,
and similarly, AKT1Myr/KRasG12D mice had significantly higher (p≤0.0013) non-fasted blood
glucose levels at 12 weeks of age compared to wild-type mice (Figure 22A). There was no
significant difference in non-fasted blood glucose levels, at any time point, when comparing
KRasG12D (RAS) mice to wild type littermates.
Doxycycline was administered to mice in order to turn off the AKT1Myr transgene. Mating
cages were arranged, as described in chapter 3, for in utero exposure, feeding regimens were
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continued at weaning, and non-fasted blood glucose levels were monitored biweekly for 9 weeks.
At weaning, the non-fasted blood glucose levels for AKT1Myr/KRasG12D mice on a standard diet
were significantly higher (p<0.0001) than all other treatment groups. There was no significant
difference between the AKT1Myr/KRasG12D mice on doxycycline and the wild type or KRasG12D
mice on either diet, and the same pattern was observed at 12 weeks (Figure 22B). At 12 weeks
AKT1Myr/KRasG12D mice also had significantly higher (p≤0.0002) fasted blood glucose levels
(Figure 22D), which is also reversible with doxycycline treatment (p<0.0001) (Figure 22E).
Weight, measured at weaning, (Figure 22F) did not differ among genotypes. However, by 12
weeks of age AKT1Myr/KRasG12D mice had significantly lower (p≤0.0002) body weight than
wildtype and KRasG12D littermates (Figure 22G). Food intake, measured at 12 weeks, (Figure
22H) did not differ among groups.

Glucose intolerance in AKT1Myr/KRasG12D transgenic mice due to insulin-glucagon imbalance.
Glucose tolerance testing (GTT) was performed at 12 weeks (n=5 males) to analyze the
ability of AKT1Myr/KRasG12D (AKTRAS) and KRasG12D (RAS) mice to clear glucose from the
blood. AKT1Myr/KRasG12D mice had a significantly higher (p=0.0003) area under the curve
(Figure 23B) compared to wild-type and KRasG12D mice, signifying glucose intolerance. The
significantly elevated blood glucose levels began prior to the glucose injection when compared to
wild type littermates and 15-minutes post injection compared to KRasG12D littermates. Blood
glucose levels were significantly elevated for all but the last time point, 120 minutes post injection
(Figure 23A).
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Serum insulin and glucagon levels, collected via cheek bleeding, revealed significant
differences

between

wild

type,

AKT1Myr/KRasG12D,

and

KRasG12D

mice.

AKT1Myr/KRasG12D mice had significantly (p<0.02) elevated insulin levels, which were evident
45 minutes after the glucose injection (Figure 23C/Table 4), but not prior to the injection.
However, AKT1Myr/KRasG12D mice had significantly (p<0.05) elevated fasted glucagon levels
(0 min), and significantly (p<0.003) lower glucagon levels 45 minutes post injection (Figure
23D/Table 4). Serum insulin and glucagon levels did not significantly differ between wild type
mice and KRasG12D littermates.

Insulin resistance in KRasG12D and AKT1Myr/ KRasG12D mice.
One week following the GTT, an insulin tolerance test (n=5 males) was performed to
analyze the sensitivity of insulin-responsive tissues in AKT1Myr/KRasG12D and KRasG12D mice.
Area under the curve was calculated (Figure 24A), blood glucose versus time, and was
significantly higher in KRasG12D (p=0.0357) and AKT1Myr/KRasG12D (p=0.0463) mice
compared to wild type mice. KRasG12D mice had significantly (p=0.006) higher blood glucose
levels at the 30 minute time point (Figure 24D).

While AKT1Myr/KRasG12D mice were

significantly higher at the 15 (p=0.01) and 30 (p=0.0328) minute time points (Figures 24C and D).

Discussion
In chapter three we characterized the early onset, prediabetic phenotype observed in
AKT1Myr mice. We highlighted a novel mechanism by which AKT1 hyperactivation induces
fasted hyperglucagonemia, leading to impaired glucose stimulated insulin secretion, glucose
intolerance, hepatic insulin resistance, and hyperglycemia via increased hepatic glucose
88

production and decreased hepatic glucose storage. In this study, which is still in progress, our goal
is to similarly characterize the diabetic phenotype observed in AKT1Myr/KRasG12D transgenic
mice, and better understand how the presence of two oncogenes (AKT1 and KRas) cooperate to
affect glucose homeostasis.
AKT1Myr/KRasG12D mice, as previously described (Albury et al. 2015) have bicistronic
regulation of myristoylated AKT1 through a Pdx1-TetA and TetO-MyrAKT1 system, as well as
Pdx-Cre–activated KRasG12D (Figure 12). As demonstrated in Chapter 3 Figure 17, this allows
the expression of myristoylated, membrane-bound and thus activated, AKT1 in the pancreas
except in the presence of doxycycline, while KRasG12D remains constitutively active within the
pancreas. KRasG12D activation alone seemed to have no effect on fasted and non-fasted blood
glucose levels. However, KRasG12D in cooperation with AKT1Myr had a more severe effect on
glucose homeostasis than AKT1Myr alone. AKT1Myr/KRasG12D (AKTRAS) mice, similar to
AKT1Myr mice, exhibited nonfasted hyperglycemia at weaning (3 weeks), regardless of sex or
weight. Unlike AKT1Myr mice, AKT1Myr/KRasG12D mice had a more severe diabetic phenotype.
This was evident by a significant increase in non-fasted blood glucose levels which averaged 309
mg/dl at 3 weeks of age and 449 mg/dl at 12 weeks of age. AKT1Myr/KRasG12D mice also
exhibited fasted hyperglycemia at 12 weeks, which was 2 months earlier than AKT1Myr mice. The
overall disease progression for AKT1Myr/KRasG12D mice was faster than AKT1Myr mice as
polyuria, muscle wasting, and bloating often required euthanization with aging. Doxycycline
treatment reduced AKT1Myr/KRasG12D blood glucose levels to wild type and KRasG12D levels,
confirming that KRasG12D alone had no effect on blood glucose levels and that the fasted and
non-fasted hyperglycemia in AKT1Myr/KRasG12D mice was largely due to AKT1 hyperactivation.
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Doxycycline treatment, if provided at an early age, also prevented the diabetes associated
symptoms (polyuria, muscle wasting, etc).
Glucose tolerance testing was performed at 12 weeks to compare the abilities of
KRasG12D and AKT1Myr/KRasG12D mice to clear glucose from the blood. AKT1Myr/KRasG12D
mice exhibited glucose intolerance, while KRasG12D activation alone had no effect on glucose
tolerance.

With the advanced disease progression noted in AKT1Myr/KRasG12D mice, we

hypothesized that they may more closely resemble the known, prediabetic AKT2 null mouse
model (AKT2KO) characterized in chapter 3 and other studies (Garofalo et al. 2003; Cho H et al.
2001). While all three models (AKT2KO, AKT1Myr/KRasG12D, AKT1Myr) exhibit glucose
intolerance, measurements of the area under the curve for AKT1Myr/KRasG12D mice more closely
resemble AKT1Myr mice. Additionally, serum insulin and glucagon levels measured during the
GTT also resemble AKT1Myr mice, with fasted hyperglucagonemia and significantly elevated
insulin secretion 45 minutes post injection.

This increase in insulin secretion, along with the

significant drop in glucagon levels, suggests that the pancreas is undergoing beta-cell
compensation, an attempt to lower blood glucose levels by secreting insulin which inhibits
glucagon secretion (Aronoff et al. 2004). Insulin and glucagon levels for KRasG12D mice did not
differ from wild-type mice.
One week following the GTT, an insulin tolerance test was performed to analyze the
sensitivity of insulin-responsive tissues in AKT1Myr/KRasG12D and KRasG12D mice, since the
elevated blood glucose levels were not due to a lack of insulin production or secretion.
Surprisingly both KRasG12D and AKT1Myr/KRasG12D mice appeared to have impaired insulin
sensitivity. While the AKT1Myr/KRasG12D impairment was more severe, the KRasG12D mice
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did exhibit elevated blood glucose levels 30 minutes post insulin injection and a significantly
higher area under the curve. Although statistically significant this impairment does not seem to
cause hyperglycemia nor glucose intolerance. Further investigation into how the pancreas, or
another insulin responsive tissue, is compensating for this impairment is necessary.
In this study we characterized the pre-tumor, diabetic phenotype of AKT1Myr/KRasG12D
mice in an attempt to better understand how KRasG12D and AKT1 oncogenes cooperate to affect
glucose homeostasis. Similar to AKT1Myr mice, yet more severe, AKT1Myr/KRasG12D mice
exhibit non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by 3 months of
age, regardless of sex. Based upon previous findings, as described in chapter 3, this hyperglycemia
is likely due to α-cell dysfunction, specifically fasted hyperglucagonemia, which induces glucose
intolerance despite increased compensatory insulin secretion, impaired insulin sensitivity,
increased hepatic glucose production, and decreased hepatic glucose storage. Collectively, this
diabetic model provides an avenue to better distinguish Type 2 Diabetes and PDAC associated
diabetes.
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Figures and Tables
Table 4: The average insulin and glucagon serum levels in wild type, RAS, and AKTRAS mice
during the glucose tolerance test.

* Indicates a significant difference. The data in this table corresponds to panels C and D in
Figure 23.
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Figure 22: AKT1Myr/KRasG12D mice have a reversible, fasted and non-fasted hyperglycemia.
Blood glucose levels were measured with a glucometer (A) at weaning (p<0.0001) and at 12 weeks
(p=0.0013). Weaning occurred at 3 weeks of age. To determine if the hyperglycemia exhibited
at weaning was reversible, breeder mice were placed on a doxycycline diet to expose the pups in
utero. Blood glucose levels were then measured (B) at weaning (p<0.0001) and at 12 weeks
(p≤0.0013). Blood glucose levels, measured at weaning were also used to identify (C) sex
differences. Mice were fasted overnight (16 hours) to determine fasted blood glucose levels (D)
at 12 weeks (p≤0.0002). Fasted blood glucose levels were also measured (E) at 12 weeks for the
mice placed on a doxycycline diet (p<0.0001). Weight was measured (F) at weaning and (G) at
12 weeks (p≤0.0002). At 12 weeks, mice were housed individually and (H) food intake was
measured daily for four days by weighing the food in the cage. Two-way ANOVA followed by
student’s t-tests within groups were used to analyze the data for figures A-C and E-F. Unpaired
student’s t-test was used for figure D and G-H. N=10 for figures A-H except D and G (n=8).
Abbreviations: Wks - week. Letters were used to illustrate significance as multiple groups are
being compared (see materials and methods for explanation).
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Figure 23: Glucose intolerance in AKT1Myr/ KRasG12D mice due to insulin-glucagon
imbalance.
Glucose tolerance testing (n=5) was performed at 12 weeks comparing: (A) wild type (WT),
KRasG12D (RAS), and AKT1Myr/KRasG12D (AKTRAS) mice. (B) Area under the curve. Data
represented as mean ± SEM (p=0.0003). Blood was collected, via cheek bleeds, at the 0- and 45minute time points to analyze serum (C) insulin and (D) glucagon levels using ELISAs. Insulin
and glucagon values are also provided in Table 4. Unpaired student’s t-tests were used to analyze
differences in area under the curve. Two-way ANOVA followed by student’s t-tests within groups
were used to analyze the data for figures C-D. Letters were used to illustrate significance as
multiple groups are being compared (see materials and methods for explanation).
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Figure 24: Insulin resistance in KRas and AKT1Myr/KRasG12D mice.
One week following the GTT, (B) an insulin tolerance test was performed (n=5). (A) Area under
the curve. Data represented as mean ± SEM (p<0.05). Unpaired student’s t-tests were used to
analyze differences in the insulin tolerance tests time points. One-way ANOVA followed by
student’s t-tests within groups were used to analyze the data for figures A and C-D. Letters were
used to illustrate significance as multiple groups are being compared (see materials and methods
for explanation).
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CHAPTER 5: CONCLUSION
Merriam Webster’s dictionary defines communication as, “the act or process of using
words, sounds, signs, or behaviors to express or exchange information.” It is important for the
body, which works as a system to be able to “communicate” with its various parts, whether organ
to organ or cell to cell. One way in which cells communicate is signal transduction, “a complex
system of communication that allows external stimuli to alter molecular activities within a cell.”
This ability of cells to perceive changes in their microenvironment and correctly respond is vital
for maintaining homeostasis, and errors in this communication system can lead to disease. Protein
Kinase B, a serine threonine kinase in the phosphatidylinositol 3-kinase (PI3K) signaling pathway,
is an important cell signaling protein, making its abnormal loss or gain of function the epicenter
of a variety of diseases, including cancer and diabetes mellitus (Manning & Cantley 2007). The
results described in this manuscript present previously unrecognized roles of AKT1
hyperactivation in the pathophysiology of pancreatic cancer and diabetes mellitus.
The hyperactivation of AKT has been conclusively linked to the development of various
human cancers, including pancreatic ductal adenocarcinoma (PDAC). PDAC is the most lethal
common cancer largely due to late diagnosis. At diagnosis, which is typically 71 years of age,
85% of PDAC patients are inoperable due to local and distant metastasis. Drug treatments are
typically ineffective at this advanced stage and the average survival rate is four to six months,
making early diagnosis a key therapeutic strategy. While it is known that activation mutations of
Ras, present in 90% of PDACs, leads to AKT activation and loss of tumor suppressors (e.g., p16
and p19), further studies into the genetic changes that occur in early PanINs may provide an
opportunity for early diagnosis and ultimately an increased survival rate (Ryan et al. 2014). .
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However, the unavailability of early-stage tissue from patients has hampered the search for such
genetic biomarkers, and made the use of pancreatic cancer mouse models of upmost importance.
By mating transgenic mice with activation of KRas (Pdx- Cre;LSL-KrasG12D) and mice
with activation of AKT1 (Pdx- Tta;TetO-MyrAKT1) we were able to produce a PDAC mouse
model with two activated oncogenes (AKT1Myr/KRasG12D). Our objective was to characterize
the incidence and frequency of histological and genetic alterations known to commonly occur in
human pancreatic cancer, as well as delineate the role of AKT1 in pancreatic tumor progression
and metastasis. We determined that AKT1 served as an accelerator increasing the frequency and
incidence of PDACs in AKTRAS mice when compared to KRasG12D (RAS) mice. We also
determined that AKT1Myr/KRasG12D mice (AKTRAS), unlike other PDAC mouse models,
accurately mimic the human PDAC progression molecularly (e.g., activation of PI3K/AKT
pathway and loss of p16Ink4a and p19Arf), structurally (e.g., positive for tissue remodeling marker
mucin-4 and fibrosis marker α-SMA), and most importantly temporally. Other PDAC models
(mice with KRasG12D activation and Pten homozygous deletion) have rapid tumor development
with mice dying at 3 weeks, while our model has a slower progression of about 54 weeks. This
better mimics the human PDAC progression as the average time frame for progression from
PanINs to PDAC is about 17 years. Ultimately, we were able to combine two oncogenic changes
important for cancer progression to accelerate tumorigenesis, while maintaining a time frame that
would align more closely with the physiological progression observed in the human disease. This
will allow us to conduct therapeutic studies that can block tumor progression at the PanIN or early
carcinoma stage, before there is excessive tissue damage.
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Understanding that the hyperactivation of AKT1 is linked to PDAC and that 80% of PDAC
patients suffer from hyperglycemia or diabetes prior to diagnosis, our next objective was to
determine how AKT1 hyperactivation affects glucose homeostasis. We characterized the early
onset, prediabetic phenotype observed in AKT1Myr mice and highlighted a novel mechanism by
which AKT1 hyperactivation affects glucose homeostasis. Beginning at weaning, 3 weeks of age,
the glucose intolerant AKT1Myr mice exhibited non-fasted hyperglycemia, which progressed to
fasted hyperglycemia by 5 months of age. The glucose intolerance was attributed to a fasted
hyperglucagonemia. Although the mechanisms behind hyperglucagonemia are still relatively
unclear, we are proposing that AKT1Myr mice, with fasted hyperglucagonemia, have impaired
GSIS, resulting in glucose intolerance despite increased compensatory insulin secretion. Hepatic
insulin resistance, an additional factor, may exacerbate the problem, preventing normoglycemia
via increased hepatic glucose production and decreased hepatic glucose storage.
AKT1Myr/KRasG12D mice, which are currently being studied, appear to display a more
severe diabetic phenotype, with fasted hyperglycemia noticeable at an earlier age (12 weeks),
fasted hyperglucagonemia, polyuria, muscle wasting, and bloating. So, similar to the oncogenesis
study, AKT1 hyperactivation appears to serve as an accelerator, increasing the severity while
decreasing the average time required for disease progression. Treatment of both models with
doxycycline diet, to turn-off the transgene, caused attenuation of the non-fasted and fasted
hyperglycemia, thus affirming AKT1 hyperactivation as the trigger.
Over the last 30 years PDAC incidence has been relatively stable (1 to 10 per 100,000
people). However, population changes, primarily the aging of 76.4 million baby boomers, are
expected to thrust pancreatic cancer from the ninth to the second leading cause of cancer-related
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deaths within the next 15 years. These newly revealed effects of AKT1 hyperactivation, along
with future studies of these mouse models, will help to better delineate the molecular mechanisms
responsible for the individual and joint roles of AKT1 and KRas in pancreatic cancer oncogenesis,
the initiation of cancer associated diabetes, and the association of these two diseases. By
thoroughly studying our AKT1Myr/KRasG12D mouse model we can identify key pre-tumor
molecular events that induce metabolic changes, distinguish PDAC associated diabetes from T2D,
and identify an early biomarker. This will ultimately lead to earlier pre-metastatic detection,
effective drug treatment, and increased PDAC survival.
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